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ABSTRACT 
α-Actinin belongs to the spectrin superfamily of proteins involved in 
cytoskeletal network, bundling or cross-linking actin filaments. Human α-actinin 
isoforms are composed of an N-terminal actin-binding domain (ABD, formed by two 
calponin like domains), a central rod domain formed by four spectrin-like repeats 
(SR1, SR2, SR3 and SR4) and a C-terminal calmodulin-like domain (CaM, formed by 
four EF-hands). Its functional unit is an antiparallel homodimer leading to a molecular 
architecture that allows the protein to cross-link actin filaments. Four different α-
actinin isoforms are present in human cells: isoforms 1 and 4 are calcium sensitive 
and found in non-muscle cells, while isoforms 2 and 3 are calcium insensitive and 
found in muscle cells. 
The muscle isoforms are regulated by the phosphoinositide PiP2 that upon 
binding to α-actinin ABD triggers conformational changes and enhances α-actinin 
binding capacity to actin filaments and other muscle proteins. Molecular details on 
interaction between PiP2 and α-actinin and concomitant conformational changes are 
not clear, but it was proposed that while the PiP2 head interacts with the N-terminal 
(ABD), the PiP2 hydrophobic tail disturbs the interaction between juxtaposed N-
terminal and C-terminal regions in the α-actinin antiparallel dimer, in particular the 
CaM domain and the neck region, which connects the ABD to the rod domain. 
A number of efforts based on binding assays and structural studies have been 
carried out in order to elucidate α-actinin regulation at molecular level with the aim to 
better understand myofibrillogenesis and enhance insights into a number of diseases.  
 In this thesis, we have performed interaction studies between PDZ domain of 
ZASP and α-actinin dimer with the aim to understand whether the hydrophobic tail of 
phosphoinositides is able to modulate this interaction. However, under the conditions 
used no interaction between PDZ domain of ZASP and α-actinin dimer was 
observed. 
 In order to further characterize the interaction between α-actinin and PiP2, we 
have designed single-site mutants of residues implicated in binding to PiP2 polar 
head and analysed them together with the wild type (WT), with a range of 
biochemical and biophysical experiments including PiP stripes, circular dichroism 
(CD), differential scanning fluorimetry (DSF), nuclear magnetic resonance 
spectroscopy (NMR), isothermal titration calorimetry (ITC) and X-ray diffraction. The 
mutants were designed based on the PiP2 binding site proposed after analysis on the 
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structure of ABD of α-actinin isoform 3. Apart from experiments with PiP strips, the 
biochemical and biophysical experiments were carried out with ABD of α-actinin 
isoform 2 and the inositols triphosphate (IP3) and hexakisphosphate (IP6), which are 
phosphoinositides head with three and six phosphate groups respectively.  
 These studies one hand showed that the ABD does not undergo any structural 
rearrangement upon binding to IP3 or IP6 and on the other, suggested that arginine 
residue at position 192 could be an important player in the ABD:PiP2 interaction, 
which is characterized by a binding constant in the milli molar range. Structural 
studies of human ABD α-actinin isoform 2 did not show IP3 bound to the domain, 
probably because of weak binding affinity and revealed ABD in the close 
conformation, similar to that found in crystal structures of ABD isoforms 3 and 4. 
In order to understand α-actinin molecular architecture and its structural 
mechanisms underlying its regulation, we carried out structural studies by single 
crystal diffraction and small angle X-ray scattering (SAXS) on full length α-actinin 
isoforms 1 and 2, α-actinin half dimers (ABD-SR1-SR2//SR3-SR4-CaM), as well as 
on Entamoeba histolytica α-actinin isoform 2, which has only two spectrin-like 
repeats. Since no crystal hits were initially obtained after extensive crystallization 
screens, the human full length muscle isoform 2 was mutated aiming to decrease the 
surface entropy of the protein. Additionally, WT and surface entropy mutant were 
submitted to protein reductive methylation. These approaches enhanced the 
propensity of the human α-actinin full length isoform 2 to crystallize, yielding crystals 
diffracting to a resolution of 4.5 Å. 
 Molecular architecture of α-actinin full length, half dimer constructs and E. 
histolytica α-actinin was characterized by SAXS. The analysis of the molecular 
envelope showed the expected protein shape and dimensions when compared with 
the determined structures of the individual domains (ABD, central rod domain and 
CaM), with CaM in close proximity of ABD domain in closed conformation. 
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ZUSAMMENFASSUNG 
α-Aktinin gehört zur Superfamilie der Spektrinproteine, die am zytoskeletalen 
Netzwerk und an der Bündelung beziehungsweise Quervernetzung von 
Aktinfilamenten beteiligt sind. Humane α-Aktinin Isoformen setzen sich aus einer N-
terminalen Aktin-Bindungsdomäne (ABD, bestehend aus zwei Calponin-artigen 
Domänen), einer zentralen Stab Domäne bestehend aus vier Spektrin-artigen 
Wiederholungen (SR1, SR2, SR3 und SR4) und einer C-terminalen Calmodulin-
artigen Domäne (CaM, bestehend aus vier EF-hands) zusammen. Die funktionelle 
Einheit ist ein antiparalleles Homodimer, dessen molekularer Aufbau dem Protein 
das Quervernetzen von Aktinfilamenten ermöglicht. In menschlichen Zellen existieren 
vier α-Aktinin Isoformen: Isoform 1 und 4 sind Calcium-sensitiv und kommen in nicht-
Muskelzellen vor, während die Isoformen 2 und 3 unempfindlich gegenüber Calcium 
sind und in Muskelzellen vorkommen. 
 Die Isoformen der Muskeln werden durch das Phophoinositid PIP2 reguliert, 
das durch die Bindung an α-Aktinin eine Konformationsänderung bewirkt und die 
Bindungskapazitäten von α-Aktinin an andere Muskelproteine erhöht. Die 
molekularen Details der Interaktion zwischen PIP2 und α-Aktinin und der 
gleichzeitigen Konformationsänderung sind nicht geklärt, jedoch wird angenommen, 
dass, während der PIP2 Kopf mit dem N-Terminus interagiert (ABD), der hydrophobe 
Schwanz von PIP2 die Interaktion zwischen dem benachbarten N-Terminus und  C-
Terminus des antiparallelen α-Aktinin Dimers stört, speziell zwischen der CaM 
Domäne und der Neck Region, die die ABD mit der Stab Domäne verbindet. 
 Unter vielen Bemühungen wurde versucht, die Regulation dieses Prozesses 
zu verstehen, wodurch die Myofibrillogenese besser verstanden und erhöhte Einsicht 
in eine Reihe von Krankheiten erzielt werden könnte. Um der Frage bezüglich der α-
Aktinin Regulation nachzugehen, wurden mehrere Bindungs- und Strukturstudien 
durchgeführt. 
 In dieser Dissertation wurden Interaktionsanalysen zwischen der PDZ Domäne 
von ZASP und dem α-Aktinin Dimer durchgeführt, um aufzuklären, ob der 
hydrophobe Schwanz des Phosphoinostids die Bindung verstärken kann. Unter den 
verwendeten Bedingungen wurde keine Interaktion beobachtet. 
 Zur weiteren Charakterisierung der Interaktion zwischen α-Aktinin und PIP2 
wurden Konstrukte mit jeweils einer Punktmutation in den Aminosäurereste erstellt, 
die bei der Bindung an die polaren Köpfe von PIP2 eine Rolle spielen. Diese wurden 
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gemeinsam mit dem Wildtyp anhand einer Reihe biochemischer und 
biophysikalischer Experimente, einschließlich PIP Strips, zircularem Dichroismus 
(CD), Differenzialfluoreszenzanalyse (DSF), Kernspinresonanzspektroskopie (NMR), 
isotherme Titration (ITC) und Rötgenstreuung analysiert. Die Mutanten basierten auf 
den PIP2 Bindungsstellen, die nach der Analyse der Struktur von ABD Isoform 3  
angenommen wurden. Abgesehen von den Experimenten mit den PIP Strips wurden 
die biochemischen und biophysikalischen Experimente mit ABD von α-Aktinin 
Isoform 2 und Inositoltriphosphat (IP3) und Hexakisphosphat (IP6) durchgeführt, 
wobei es sich um Phosphoinositid Köpfe mit drei beziehungsweise sechs 
Phosphatgruppen handelt. 
 In Strukturanalysen von humanem α-Aktinin Isoform 2 ABD war IP3 nicht an 
die Domäne gebunden, wahrscheinlich auf Grund geringer Bindungsaffinität, und 
zeigten ABD in geschlossener Konformation, entsprechend den Kristallstrukturen von 
ABD Isoformen 3 und 4. 
Um den molekulare Aufbau von α-Aktinin und den strukturellen Mechanismus, 
der seiner Regulation zu Grunde liegt zu verstehen, wurden Strukturanalysen von 
Einzelkristallen und Kleinwinkelstreuung (SAXS) an vollständigem α-Aktinin Isoform 
1 und 2, dem halben Dimer (ABD-SR1-SR2//SR3-SR4-CaM), als auch an 
Entamoeba histolytica α-Aktinin Isoform 2, das nur zwei Spektrin-artige 
Wiederholungen hat, durchgeführt. Alle Konstrukte wurden umfassenden 
Kristallisations-Screens unterzogen. Da anfangs keine Kristallisationstreffer erzielt 
werden konnten, wurde die vollständige menschliche Muskelisoform 2 mutiert, um 
die Oberflächenentropie des Proteins zu verringern. Zusätzlich wurden Wildtyp und 
Oberflächenentropie-Mutanten reduktiver Methylierung unterzogen. Diese Ansätze 
erhöhten die Wahrscheinlichkeit von humanem α-Aktinin Isoform 2 zu kristallisieren, 
und hatten Kristalle zum Resultat, die bei einer Auflösung von 4.5 Å streuten. 
 Der molekulare Aufbau des vollständiges α-Aktinin, der Konstrukte des halben 
Dimers und E. histolytica α-Aktinin, wurden durch SAXS charakterisiert. Die Analyse 
der molekularen Hülle zeigte die erwartete Proteinform und Größe, nachdem sie mit 
den aufgeklärten Strukturen der einzelnen Domänen (ABD, zentrale Stab Domäne 
und CaM) verglichen wurden, mit CaM in enger räumlicher Nähe zu ABD, das in 
geschlossener Konformation vorlag. 
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1. INTRODUCTION 
 
1.1 α-actinin 
α-Actinin is a ubiquitously conserved protein that cross-links actin filaments. It 
belongs to the spectrin superfamily of proteins, an important group of actin-binding 
proteins, which also encloses spectrin, utrophin and dystrophin. These proteins are 
involved in functions that requires cross-linking, bundling or binding to actin filaments. 
Phylogenetic analysis shows that this large functional variety within the family arose 
through alternative splicing and gene duplication of a common ancestral α-actinin 
gene (Baines, 2003; Broderick and Winder, 2005; Thomas et al., 1997; Viel, 1999; 
Virel and Backman, 2004, 2007).  
Proteins from spectrin family are involved in several diseases, e.g. familial 
focal segmental glomerulosclerosis (FSGS), Duchenne muscular dystrophy (DMD) 
and hereditary spherocytosis [HS; reviewed by (Broderick and Winder, 2005; Kaplan 
et al., 2000)]; hepatitis C (Lan et al., 2003), among others. 
α-Actinin isoforms have been characterized genetically and/or biochemically 
from a large variety of taxa, from protists to mammals (Arimura et al., 1988; Barstead 
et al., 1991; Beggs et al., 1992; Fyrberg et al., 1990; Honda et al., 1998; Noegel et 
al., 1987). Regarding expression patterns, biochemical characteristics, tissue and 
sub-cellular location, α-actinin proteins can be grouped into two different classes: 
non-muscle cytoskeletal isoforms (section 1.1.1) and muscle isoforms (section 1.1.2). 
The first ones are calcium sensitive while the latter are calcium insensitive (Blanchard 
et al., 1989; Burridge and Feramisco, 1981; Otto, 1994). 
Apart from its mechanical role involved in cell shape and locomotion by 
conferring both stability and plasticity to actin-based arrays (Xu et al., 1998), α-actinin 
plays several important roles in the cell, such as linking the cytoskeleton to different 
transmembrane proteins in a variety of junctions, regulating the activity of a number 
of receptors and being a scaffold to connect the cytoskeleton to diverse signalling 
pathways (Blanchard et al., 1989; MacArthur and North, 2004; Otey and Carpen, 
2004; Virel and Backman, 2004). 
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1.1.1 Cytoskeleton 
 The cytoskeleton is a dynamic structure present in the cytoplasm of 
prokaryotic [reviewed by (Michie and Lowe, 2006; Shih and Rothfield, 2006)] and 
eukaryotic [reviewed by (Frixione, 2000)] cells, composed of highly organized 
filamentous systems. It plays important roles in living cells, being involved in 
establishing cell shape, locomotion, intracellular transport and cell division. Its 
structure is built up by three main types of protein filaments: actin filaments 
(microfilaments), intermediate filaments and microtubules. These filaments can be 
assembled in bundles or networks by several actin-binding proteins depending on 
their size and flexibility [reviewed by (Sjoblom et al., 2008a)]. 
 One important actin-binding protein is α-actinin, the central focus of this thesis, 
which bundles actin filaments (Zamir and Geiger, 2001). 
 In cytoskeleton two α-actinin isoforms are found, the non-muscle isoforms 1 
and 4, which are commonly associated with focal contacts (Figure 1.1) and stress 
fibers (Edlund et al., 2001; Otey and Carpen, 2004; Pavalko and Burridge, 1991). In 
migrating cells, their distribution differs since the α-actinin isoform 1 is more abundant 
in actin stress fibers, while the isoform 4 is more abundant in circular dorsal ruffles 
(Araki et al., 2000; Honda et al., 1998; Nikolopoulos et al., 2000). 
 
1.1.2 Striated muscle 
 Muscle is the contractile tissue of vertebrates’ body and can be found in two 
major types: smooth (visceral) and striated (cardiac and skeletal). The striated 
muscles are formed of fibres (Figure 1.2A), which in turn are built by myofibrils 
(Figure 1.2B), which themselves are formed of repeating units called sarcomeres 
[Figure 1.2C; reviewed by (Squire et al., 2005)]. 
 The sarcomere is the contractile unit of the muscle composed of three 
filamentous systems: thin filaments (actin), thick filaments (myosin) and titin/nebulin 
filaments. Titin is a giant multidomain protein that spans half sarcomeres (Granzier 
and Labeit, 2007; Granzier and Labeit, 2005; Maruyama, 1997) and acts as a 
molecular ruler organizing the actin filaments by interacting with several sarcomeric 
proteins, including α-actinin (Trinick, 1996). 
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Figure 1.1 Schematic view of the cytoskeleton in focal contacts where α-actinin (red) links actin 
filaments (blue) to membrane associated proteins: vinculin (green), talin (orange), integrin (brown) and 
tensin (purple). Modified from (Sjoblom et al., 2008a). 
 
 The boundary between sarcomeres is the Z-disk (Figure 1.2D), a highly 
specialized structure that maintains the organization of the sarcomere and is 
responsible for the connection between two sarcomeres. It is a multi-protein complex 
where the most aboundant component is α-actinin. 
In Z-disk, α-actinin cross-links antiparallel actin filaments coming from adjacent 
sarcomeres, forming a lattice-like structure that stabilizes the muscle contractile 
apparatus and acts as a scaffold for many other proteins interaction [Figure 1.2D; 
(Clark et al., 2002; Masaki et al., 1967; Squire, 1997)]. 
 Similarly to the non-muscle isoforms, α-actinin muscle isoforms 2 and 3 are 
distributed differently in muscle tissues. While the isoform 2 is the major isoform in 
the cardiac and oxidative skeletal muscle, the isoform 3 is largely expressed in 
glycolytic skeletal muscle fibers (Mills et al., 2001). 
 Fluorescence and photo-bleaching studies have shown that the integrity of 
sarcomeric α-actinin is important for formation, maintenance and dynamics of the Z-
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disk since this protein is present during all stages of the myofibrillogenesis as well in 
the mature muscle (Stout et al., 2008; Wang et al., 2005). 
 
 
 
Figure 1.2 Schematic view of striated muscle. A) muscle fibre; B) myofibril; C) sarcomere; D) 
sarcomeric Z-disk where α-actinin (red) cross-links antiparallel actin filaments (blue) and interacts with 
titin (gray), ZASP (yellow), ALP (purple), MLP (orange), FATZ (green), among others. Modified from 
http://www.ucl.ac.uk/~sjjgsca/MuscleSarcomere.gif, (Clark et al., 2002) and (Sjoblom et al., 2008a). 
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1.2 α-actinin molecular architecture 
 All members of the spectrin superfamily have at their N-terminal a 
characteristic actin-binding domain (ABD), composed of two consecutive calponin 
homology domains (CH); followed by spectrin-like repeats (SR) and EF-hands. 
 The functional unit of α-actinin is an antiparallel homodimer, composed of an 
ABD, connected via a flexible neck region to four spectrin-like repeats (SR1-SR4), 
forming the central rod that is followed by a C-terminal calmodulin-like domain (CaM), 
formed by 4 EF-hands (Castresana and Saraste, 1995; Davison and Critchley, 1988; 
Trave et al., 1995). This molecular architecture results in the formation of a rod-
shaped molecule with functional domains (ABD and CaM) at both ends (Figure 1.3), 
allowing the protein to cross-link actin filaments (Young and Gautel, 2000). 
 
 
 
Figure 1.3 Schematic representation of human α-actinin antiparallel homodimer with its domains: ABD 
(light blue), SR1-SR4 (orange, green, red and pink respectively) and CaM (dark blue). 
 
1.2.1 Actin-binding domain (ABD) 
 The ABD of α-actinin isoforms is the most conserved domain within the protein 
family, reflecting the evolutionary high conservation of its binding partner: actin 
(Sheterline et al., 1995). This domain consists of a tandem pair of type 1 and type 2 
calponin homology domains (CH1, CH2), found in several actin-binding proteins, 
including most of the spectrin superfamily proteins and also in fimbrins, 
parvins/actopaxins/affixins (Gimona et al., 2002). 
 The crystal structures of ABD domains from numerous actin binding proteins 
have already been determined: Arabidopsis thaliana and Schizosaccharomyces 
pombe fimbrin (Goldsmith et al., 1997; Klein et al., 2004), utrophin (Keep et al., 
1999), dystrophin (Norwood et al., 2000), human and mouse plectin (Garcia-Alvarez 
et al., 2003; Sevcik et al., 2004), as well as human a-actinin 1, 3, and 4 (Borrego-
Diaz et al., 2006; Franzot et al., 2005; Lee et al., 2008). In all structures, the ABD 
adopts a closed conformation (Figure 1.4), except for A. thaliana fimbrin that has 
unique mutations at the CH1-CH2 interface [reviewed by (Sjoblom et al., 2008b)]. 
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Figure 1.4 Domain organization of human α-actinin ABD isoform 3 in closed conformation [PDB entry 
WKU; (Franzot et al., 2005). CH1 is coloured in green, CH2 in red and the connecting linker in yellow. 
Highlighted with ball and sticks are the conserved residues, K250 and W142, which are important for 
the interaction between the CH domains. Modified from (Sjoblom et al., 2008a). 
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Each individual CH domain is composed of four principal helices (A, C, E and 
G) that form the core of the domain. Helices C and G are parallel to each other and 
are sandwiched between the N-terminal helix A and helix E.  
The closed arrangement of CH1-CH2 in ABD is achieved in a similar manner 
in all ABD domains: helices A and G of CH1 pack against the C-terminal region of 
CH2 [helices F and G; Figure 1.4; reviewed by (Sjoblom et al., 2008a; Sjoblom et al., 
2008b)]. The nature of the CH1-CH2 domain interface is semi polar, part is 
hydrophobic and part is polar contacts that stabilize the interaction between the two 
domains (Borrego-Diaz et al., 2006; Franzot et al., 2005). 
A detailed analysis of the inter-domain interface and of the conservation of 
amino acid residues involved revealed a critical and highly conserved interaction 
between the tryptophan residue 128 at CH1 (W128 of helix G) and the lysine residue 
236 at CH2 [K236 of helix G; numbers corresponding to human α-actinin isoform 1; 
(Banuelos et al., 1998; Borrego-Diaz et al., 2006)], which form hydrophobic 
interactions (Crowley and Golovin, 2005). In isoform 3, these residues correspond to 
W142 and K250, highlighted in Figure 1.4. 
Interestingly, the crystal structure of human ABD α-actinin isoform 4 mutant 
K255E (K255 corresponds to the position 236 in isoform 1 and position 250 in 
isoform 3, Figure 1.4), involved in familial focal segmental glomerulosclerosis, 
displays the same closed conformation as observed in other ABD domains, 
suggesting that the compact conformation is a highly stable structure in typical ABD 
(Lee et al., 2008). 
Mutational, cross-linking and NMR studies on ABD from different proteins have 
identified three actin binding sites [ABS1-3; (Bresnick et al., 1991; Bresnick et al., 
1990; Corrado et al., 1994; Fabbrizio et al., 1993; Gimona and Winder, 1998; 
Hemmings et al., 1992; Kuhlman et al., 1992; Levine et al., 1990, 1992; Way et al., 
1992; Winder et al., 1995)]. These sites map to the N-terminal of CH1 at helix A 
(ABS1: residues 48-57), the C-terminal of CH1 at helix G (ABS2: residues 123-147) 
and to the interdomain linker flanked by the N-terminal α-helix of CH2 domain [ABS3: 
residues 153-172; numbers corresponding to human α-actinin isoform 3; Figure 1.5 
(Franzot et al., 2005)]. 
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Figure 1.5 Actinin-binding sites (ABS) of α-actinin ABD. ABS1 is coloured in green, ABS2 in yellow 
and ABS3 in red. Modified from (Sjoblom et al., 2008a). 
 
1.2.2 Central rod domain (SR) 
 The central rod region of a human α-actinin isoform is composed of four 
consecutive spectrin-like repeats (SR). However, the number of the repeats has 
changed during evolution and the central rod domain appears to be the least 
conserved region of the α-actinin. All known vertebrate α-actinin molecules contain 
four SR, while the fungus S. pombe and the parasite Trichomonas vaginalis have two 
SR (Wu et al., 2001) and five SR (Bricheux et al., 1998), respectively. The protozoan 
Entamoeba histolytica has one or two SR depending on which protein isoform (Virel 
et al., 2007; Virel and Backman, 2004, 2006). 
 The three-dimensional structure of a single spectrin-like repeat adopts a triple 
helix coiled-coil bundle. Such a structure of the repeating unit was predicted on the 
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basis of amino acid sequence analysis of spectrin (Speicher and Marchesi, 1984) 
and has been observed in a number of structures coming from the spectrin 
superfamily of proteins (Djinovic-Carugo et al., 1999; Grum et al., 1999; Kliche et al., 
2001; Kusunoki et al., 2004a; Kusunoki et al., 2004b; Pascual et al., 1997; Yan et al., 
1993; Ylanne et al., 2001a). 
 In the spectrin superfamily, the number of SR controls the specific distance 
between the domains at the N-terminal and C-terminal, and therefore, the length and 
flexibility of the cross-linker (Winder, 1997). In human α-actinin, the central rod 
domain forms an antiparallel homodimer (Ylanne et al., 2001a, b) with an overall 
length of 240 Å and width between 40-50 Å (Figure 1.6). The repeating units are 
connected by short linkers, providing structural rigidity to the subunit and to the 
dimer, a feature required for its primary function, bundling of actin filaments. 
 
 
 
Figure 1.6 Rod domain structure [PDB entry 1HCI; (Ylanne et al., 2001b)], showing the dimer 
organization with the spectrin-like repeats coloured in blue for SR1, green for SR2, yellow for SR3 and 
red for SR4. Modified from (Sjoblom et al., 2008a). 
 
On the contrary, structure determination of a repeat pair of α-spectrin in 
multiple crystal lattice conditions (Grum et al., 1999) and subsequent studies on 
different double and triple spectrin-like repeat constructs (Kusunoki et al., 2004a; 
Kusunoki et al., 2004b) revealed inherent flexibility between repeats, a characteristic 
long assumed from the flexible nature of the erythrocyte membranes (Winkelmann 
and Forget, 1993). 
Intrinsic structural flexibility of the α-actinin dimer is required to carry out 
bundling of different arrays of actin filaments (Djinovic-Carugo et al., 1999; Ylanne et 
al., 2001a): while in skeletal and cardiac muscle, α-actinin cross-links antiparallel 
actin filaments coming from adjacent sarcomeres (Figure 1.2), in non-muscle and 
smooth muscle cells actin filaments are not part of an organized lattice, and can 
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therefore assume very diverse orientations (Figure 1.1). The built-in flexibility resides 
in the neck region of α-actinin, connecting the ABD to the central rod domain, 
consenting ABD to adopt variable orientations with respect to the main body of α-
actinin. 
A marked feature of the α-actinin central rod domain is its 90° twist along the 
long axis of the dimer. Analysis of the inter-subunit interface shows an extensive list 
of polar (42%) and non-polar (58%) contacts, burying about 11% of the solvent 
accessible area of the monomer (Ylanne et al., 2001a), in agreements with the high 
affinity of dimer formation in the pico molar range (Flood et al., 1995; Flood et al., 
1997). 
 The electrostatic potential of the dimer interface surface shows a gradient from 
basic in SR1 to acidic in SR4, well conserved throughout the isoforms and species, 
leading to formation of aligned antiparallel dimer. 
 α-Actinin central rod surface is characterised by an extend acidic electrostatic 
potential, and was proposed to act as a docking scaffold, offering two binding sites at 
a time due to the internal symmetry of the rod domain (Ylanne et al., 2001a). 
 
1.2.3 Calmodulin-like domain (CaM) 
 The C-terminal calmodulin-like domain (CaM) of α-actinin is composed of four 
EF-hand motifs, which exhibit functional divergence between α-actinin isoforms. The 
EF-hands of non-muscle isoforms (1 and 4) bind calcium, regulating in this way the 
actin-binding activity of the molecule, while the EF-hands of muscle isoforms lost this 
ability [α-actinin regulation details are presented in section 1.3; (Burridge and 
Feramisco, 1981; Fukami et al., 1992; Tang et al., 2001)]. 
 EF-hands are helix-loop-helix motifs involved in binding intracellular calcium. 
Generally, EF-hands come in side-by-side pairs, forming a globular domain capable 
of coordinating up to two calcium (Ca2+) ions (Lewit-Bentley and Rety, 2000). Ca2+ 
binding triggers a major conformational change of the globular domain from a closed 
state to an open one, causing a rearrangement of the α-helices and exposure of 
hydrophobic residues to the surface of the protein, allowing the protein to interact 
with specific targets (Ikura, 1996). 
In a subset of EF-hand family of proteins, motifs have diverged to the extent 
that they have partially or entirely lost the capacity of taking Ca2+ (Nakayama and 
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Kretsinger, 1994), which can be observed in α-actinin muscle isoforms (2 and 3; 
section 1.3). 
 In striated muscle, for instance, the CaM domain of α-actinin muscle isoforms 
is involved in targeting the α-actinin to the Z-disk via binding to titin and other proteins 
(Young et al., 1998; Young and Gautel, 2000)]. The region of titin that binds to CaM 
domain of α-actinin consists of a series of repeated sequence motifs of about 45 
residues, termed Z-repeats [more specifically Z-repeat 7; (Ohtsuka et al., 1997; 
Sorimachi et al., 1997)]. 
 The structure of EF-3/4 of human α-actinin isoform 2 was determined in 
complex with the titin Z-repeat 7 by nuclear magnetic resonance spectroscopy [NMR 
(Atkinson et al., 2001)]. The Z-repeat 7 of titin binds to the groove formed by the two 
semi open lobes of the two EF hands (Figure 1.7). Upon complex formation Z-repeat 
7 adopts an α-helical structure and binds with nano molar affinity to EF-3/4 (Au et al., 
2004; Joseph et al., 2001). 
 
 
 
Figure 1.7 Structure of α-actinin EF-3/4 (green) in complex with titin Z-repeat 7 [red; PDB entry 1H8B; 
(Atkinson et al., 2001)]. 
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1.3 α-actinin regulation 
 Four mechanisms of α-actinin regulation are known: binding of calcium (Ca2+), 
binding of phosphatidylinositol, processing by proteases and phosphorylation by 
tyrosine kinases [reviewed by (Otey and Carpen, 2004)]. 
 It has been shown that the binding of α-actinin to actin filaments can be 
regulated by calcium and/or phosphatidylinositol depending on the isoform. Non-
muscle isoforms (1 and 4) are regulated by Ca2+ (Burridge and Feramisco, 1981), 
while muscle isoforms (2 and 3) are regulated by binding of the phosphoinositide 
phosphatidylinositol 4, 5-biphosphate [PiP2; (Fukami et al., 1992)]. 
 The actin binding properties of the non-muscle molecules are reduced or even 
abolished at calcium concentration higher than 10-7 M and pH 7.0 (Condeelis and 
Vahey, 1982; Fechheimer et al., 1982; Noegel et al., 1987; Witke et al., 1993). At 
lower concentrations the viscosity of F-actin is significantly increased by the α-actinin 
isoforms 1 and 4 (Blanchard et al., 1989; Otey and Carpen, 2004). The detailed 
mechanism of calcium and α-actinin interaction is still unknown. 
 The Ca2+ insensitivity of the muscle isoforms is determined by mutations on 
the Ca2+ coordinates within the CaM domain that diverges considerably from the 
classical consensus. Consequently, these isoforms lost the properties of Ca2+ binding 
(Beggs et al., 1992; Blanchard et al., 1989). It was speculated that during evolution of 
α-actinin the ancestral gene encoded a Ca2+ sensitive isoform, while the calcium 
insensitive isoforms arose with the development of the muscle tissue, where the actin 
binding regulation should be independent of the Ca2+ flux (Blanchard et al., 1989). 
 The current muscle isoforms regulation model proposed by Young and Gautel 
(2000) pictures the interaction between N-terminal and C-terminal of the two 
subunits. This model states that the CaM domain of one subunit interacts with the 
neck region, between the ABD and the first spectrin-like repeat (SR1) of the other 
subunit. This interaction prevents the binding of the protein to various partners. 
However, in the presence of the phosphoinositide PiP2, conformational changes are 
trigged which release this interaction and make CaM domain free to bind to its 
partners (Figure 1.8) such as titin (Atkinson et al., 2001; Joseph et al., 2001; Young 
et al., 1998) and the PDZ domain of ZASP (Au et al., 2004; Faulkner et al., 1999). 
These conformational changes enhance the actin binding capacity of α-actinin 
(Young and Gautel, 2000). 
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 How the phosphoinositide is able to release the interaction between the CaM 
domain and the neck is not known at molecular level. It is believed that its polar head 
group interacts with the ABD, while the tail interferes with the interaction between the 
CaM domain and the neck (Young and Gautel, 2000). The phosphate groups 4 and 5 
of the phosphoinositide head group interact with the second calponin homology 
domain (CH2) of ABD (Fraley et al., 2003). The binding site within CH2 domain was 
mapped by immunoassays and site-directed mutagenesis (Fukami et al., 1996) to the 
amino acids 168-184 (numbers corresponding to the sequence of chicken skeletal 
muscle α-actinin isoform). 
 
 
 
Figure 1.8 Schematic representation of the α-actinin regulation model. A) Inactive state: the CaM 
domain of one subunit interacts with the neck of the other subunit. B) Active state: upon binding of 
PiP2, conformational changes are triggered that releases the CaM domain to bind to its patterns, such 
as titin (dark gray) or ZASP (dark yellow). Modified from (Sjoblom et al., 2008a). 
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 Subsequently, analysis of the three-dimensional crystal structure of the human 
ABD isoform 3 (Franzot et al., 2005) suggested that the most probable region for the 
binding of the phosphate group of the phosphoinositide PiP2 to the CH2 domain 
comprises the positively charged arginine residues R170, R176 and R199 (numbers 
corresponding to α-actinin isoform 3; Figure 1.9), which are present only in the CH2 
domain of α-actinin muscle isoforms (Gimona et al., 2002). These residues follow the 
pattern observed in structures solved with others phosphoinositides head group 
bound to proteins and, moreover, their relative solvent accessibility of the polar side 
chain is suitable for binding (Franzot et al., 2005). 
 
 
 
Figure 1.9 PiP2 proposed binding site within ABD of α-actinin isoform 3. Solvent accessible surface of 
ABD is coloured by electrostatic potential. Residues identified as putative PiP2 ligands are highlighted 
in sticks: R170, R176 and R199. Modified from (Sjoblom et al., 2008a). 
 
 Immunofluorescence assays showed the relationship between the 
phosphoinositide PiP2 synthesis and sarcomeric Z-disk, suggesting that the 
requirement of PiP2 for the activation of α-actinin is necessary during the Z-disk 
formation in developing muscle (Young and Gautel, 2000). 
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 However, there are some controversies about the regulation of α-actinin by 
phosphoinositides. Not only PiP2 is involved in the regulation of α-actinin, as 
described above, but also the phosphatidylinositol 3, 4, 5-triphosphate (PiP3). It has 
been shown that in non-muscle cells, the binding of PiP2 or PiP3 decreases the actin 
binding capacity of α-actinin (Corgan et al., 2004; Fraley et al., 2003; Full et al., 2007; 
Greenwood et al., 2000). It remains an opened question awaiting elucidations. 
 As already mentioned, apart from these processes of regulation described: 
Ca2+ and PiP binding, two other regulatory mechanisms have been identified: 
processing by proteases and phosphorylation by tyrosine kinases (Otey and Carpen, 
2004). 
 The proteolytic process is carried out by calpain, which cleaves proteins 
involved in integrin mediated adhesions and actin-based membrane protrusions 
during cell migration (Franco et al., 2004). Calpains are regulated not only by 
calcium, depending on the protease isoform (Lebart and Benyamin, 2006), but also 
by phosphoinositides PiP2 and PiP3, which in turn modulate autolysis of calpain and 
proteolysis of α-actinin by calpain (Saido et al., 1992). Sprague et al. (2008) have 
shown that the susceptibility of α-actinin to calpain isoform 1 cleavage is decreased 
by PiP2 and increased by PiP3, while the cleavage by calpain isoform 2 is not 
influenced by PiP2. The same group also mapped the calpain isoform 2 cleavage site 
in presence of PiP3 to the final helix of the CH2 domain of α-actinin [after the tyrosine 
residue 246 (Y246) in chicken gizzard α-actinin; (Sprague et al., 2008)]. 
 Tyrosine phosphorylation regulation is mediated by an integrin-activated 
tyrosine kinase focal adhesion kinase (FAK), a regulator of adhesion plaques and cell 
motility. FAK phosphorylates the ABD domain of α-actinin on the Y12 of the non-
muscle human isoform, reducing its affinity to actin filaments (Izaguirre et al., 2001) 
and suggesting α-actinin as a target for signalling pathways, which regulate cell 
adhesion. It was proposed that the decrease of affinity for actin filaments changes the 
mechanical properties of the cytoskeleton, leading to enhanced cell motility (Izaguirre 
et al., 2001). 
 
1.4 α-actinin interactions 
 In addition to interaction with actin filaments, α-actinin can interact with many 
cytoskeletal and regulatory proteins, acting as a multivalent platform for several 
protein-protein interactions (Djinovic-Carugo et al., 2002; MacArthur and North, 2004; 
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Otey and Carpen, 2004). A comprehensive overview of the functional categories that 
demonstrate α-actinin versatility involved in structural, signalling and metabolic roles 
can be found in others reviews (Clark et al., 2002; Djinovic-Carugo et al., 2002; 
Ervasti, 2003; Faulkner et al., 2001; MacArthur and North, 2004; Otey and Carpen, 
2004; Sjoblom et al., 2008a). 
 
1.4.1 ZASP 
 An important binding partner of α-actinin muscle isoform is the sarcomeric 
protein ZASP (Z-band Alternatively Spliced PDZ-motif protein), found in striated 
muscle with different variants derived from alternative splicing (Faulkner et al., 1999). 
ZASP is a human orthologue of cypher (mouse) and several cardiac and muscle 
diseases are associated to the Cypher/ZASP family of proteins [reviewed by (Sheikh 
et al., 2007)]. 
 ZASP is composed of an N-terminal PDZ domain, which is the only common 
domain within the family. ZASP variants present different numbers of LIM domains, 
while ZASP itself has none, being therefore a truncated form of PDZ/LIM proteins 
(Faulkner et al., 1999). 
 PDZ domains are protein-protein interaction modules composed of 80-120 
residues (Xia et al., 1997), consisting mainly of six β-strand (βA- βF) and two α-
helices (αA and αB), folded into a β sandwich. C-terminal residues of PDZ partners 
bind to the groove formed between αB and βB [reviewed by (Hung and Sheng, 
2002)]. 
PDZ domains can interact with other proteins in four different manners: binding 
to C-terminal (Kornau et al., 1995; Sato et al., 1995), to internal peptides (Shieh and 
Zhu, 1996), to PDZ domains (Brenman et al., 1996) or to LIM domains (Cuppen et 
al., 1998) of their partners. The binding specificity is determined by the interaction 
between the first residue of the helix αB and the side chain of the C-terminal ligand, 
at position 2. According to the type of interactions between the PDZ and ligand, PDZ 
domains can belong to three different classes, namely 1, 2 and 3 [reviewed by (Hung 
and Sheng, 2002)]. The class 1 PDZ domains interact via hydrogen bonds to their 
ligand, the class 2 domains bind to their partners via hydrophobic interactions and the 
class 3 domains have a preference for negatively charged residues to perform the 
interaction. 
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 Experiments have shown that the interaction between ZASP and α-actinin has 
been mapped to the PDZ domain of ZASP and C-terminal (EF-3/4) of α-actinin 
isoform 2, more specifically to EF-3/4, suggesting that ZASP and titin bind to α-
actinin around the same region (Faulkner et al., 1999; Zhou et al., 2001). 
 The structure of PDZ domain of ZASP was determined by NMR (Au et al., 
2004) and revealed a typical class 1 PDZ domain (Figure 1.10). The same study also 
showed that the affinity between PDZ and the EF-3/4 of α-actinin is relatively weak 
(micro molar range) in comparison with other PDZ domains and their binding 
partners. Moreover, it was shown that ZASP and titin have distinct binding sites 
within the α-actinin C-terminal, rendering it possible for the two proteins to interact 
with α-actinin at the same time (Au et al., 2004). 
 
 
 
Figure 1.10 Structure of PDZ domain of ZASP [PDB entry 1RGW; (Au et al., 2004)]. The binding 
between PDZ and C-terminal partners is localized in the groove between αB (pale green) and βB (pale 
blue). 
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2. AIM OF THE THESIS 
Understanding the regulation of α-actinin’s interaction with actin filaments and 
several other binding partners is very important for comprehension of its functions in 
Z-disk of striated muscle. The current model was suggested by Young and Gautel 
[section 1.3; (Young and Gautel, 2000)] who proposed that PiP2 regulates the 
binding of α-actinin muscle isoforms to actin filaments, titin (Atkinson et al., 2001; 
Joseph et al., 2001; Young et al., 1998) and ZASP (Au et al., 2004; Faulkner et al., 
1999). The interaction between α-actinin and PiP2 has not yet been characterised at 
molecular detail, but it is believed that while the polar head interacts with the α-actinin 
ABD, its hydrophobic tail interferes with the interaction of between CaM-like domain 
of one and the neck region of the juxtaposed α-actinin in the antiparallel dimer, 
releasing the functional domains ABD and CaM to interact with their binding partners. 
 Although a body of structural data is available on individual domains of 
α-actinin (ABD, central rod domain and EF-3/4 of CaM; section 1.2), no structural 
information so far exists on the entire molecule or its smaller functional units, e.g. on 
half dimer or on the complex of the actin-binding domain and first spectrin-like repeat 
(ABD_SR1) bound to CaM domain or EF-3/4. The aim of this work is to generate 
structural information to address questions concerning α-actinin structure and 
regulation by employing a combination of biochemical, biophysical and structural 
studies. 
 Specific aims are: 
 
1- Interaction studies 
 Analysis of the influence of the phosphoinositides on the 
interaction of α-actinin isoform 2 and PDZ domain of ZASP in the 
context of α-actinin antiparallel dimer; 
 Validation of the proposed PiP2 binding site of α-actinin 
muscle isoform (Franzot et al., 2005) through binding studies of ABD 
and mutants of residues implicated in biding to inositol triphosphate 
(IP3) or inositol hexakisphosphate (IP6), which are the soluble heads of 
phosphoinositides. 
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2- Structural studies 
 Validation of the proposed PiP2 binding site on ABD 
(Franzot et al., 2005) through X-ray diffraction studies of ABD in 
complex with IP3 or IP6; 
 Generation of high resolution structural information on α-
actinin isoforms 1 and 2 full length (AFL), half of the dimer 
(ABD_SR1_SR2//SR3_SR4_CaM; hd) and smaller functional units 
through single crystal X-ray diffraction analysis in order to understand 
α-actinin architecture at molecular detail; 
 Generation of high resolution structural information on 
Entamoeba histolytica α-actinin isoform 2 full length (2Eh; smaller 
version of human isoforms with two spectrin repeats) through single 
crystal X-ray diffraction analysis to understand α-actinin architecture at 
molecular detail; 
 Generation of molecular models based on SAXS-derived 
molecular envelope of human α-actinin isoforms 1 and 2, and E. 
histolytica α-actinin isoform 2 to gain understanding of α-actinin 
molecular architecture. 
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3. MATERIALS AND METHODS 
 
3.1 Constructs and nomenclature 
 The constructs designed for this study are showed in Figure 3.1. For human α-
actinin constructs the residues are numbered according to the sequence of human α-
actinin isoform 2 (Figure 3.1A – I). Constructs for human α-actinin isoform 1 were 
based on the sequence alignment between the two isoforms (1 and 2). The full length 
human α-actinin isoforms 1 and 2 (1AFL, 2AFL) and the half dimer (1hd, 2hd) were 
cloned into pET8c and kindly supplied by the group of Dr. Jari Ylänne (University of 
Jyväskylä). 
 Regarding the nomenclature, numbers in front of the construct abbreviations 
denote the corresponding α-actinin isoform (1 = non-muscle isoform or 2 = muscle 
isoform). Constructs with the suffix Y start at tyrosine residue 19 (Y19) and those with 
the suffix a start at the beginning of the actin binding domain (ABD, A35). 
 For Entamoeba histolytica α-actinin isoform 2 (2Eh), only the full length 
construct was used (Figure 3.1J) and it was cloned into pET19b by our collaborators, 
the group of Dr. Lars Backman (University of Umeå). 
 
3.2 DNA manipulation 
3.2.1 DNA amplification (PCR) and colony PCR 
 The PCR reaction was prepared to a final volume of 20 µl: 1.25 mM MgCl2, 
0.25 mM dNTP’s, 2.5 units of Taq Polymerase, 1x PCR buffer (10 mM Tris-HCl pH 
8.0, 50 mM KCl, 0.08% Nonidet P-40), 10 pmol of each oligonucleotide 
(forward/reverse) and 10 to 20 ng DNA template. The cycles of individual PCR 
reactions were optimized according to the length of the amplification product and the 
oligonucleotides melting temperature (Tm; Table 3.1). 
 For colony PCR (used to identify positive clones) the reaction was similar to 
the DNA amplification described above, however, the template used was the mixture 
containing a dilution of a colony in 100 µl Milli-Q water. This mixture was incubated at 
95° C during 5 min, centrifuged to precipitate the debris (5000 g, 5 min, at room 
temperature) and 1 µl of the supernatant was used as template for the colony PCR 
reaction. 
_________________________________________________MATERIALS AND METHODS 
21 
 
3.2.1.1 α-actinin 
 The α-actinin target fragments were amplified by PCR using the full length 
fragment cloned into pET8c (by Dr. Jari Ylänne) as template. For all constructs 
specific oligonucleotides were designed including the restriction sites for BsaI 
(forward) and KpnI (reverse; Table 3.1). 
 
3.2.1.2 PDZ domain of ZASP 
 The PDZ domain was amplified by PCR using the ZASP full length fragment 
cloned into pUC vector (by the group of Dr. Georgine Faulkner; ICGEB; Italy) as a 
template. Specific oligonucleotides were designed including the restriction sites for 
NcoI (forward) and KpnI (reverse; Table 3.1) 
 
3.2.2 DNA agarose gel electrophoresis 
 DNA samples were resolved by DNA agarose gel in concentrations ranging 
from 0.7% (w/v) to 1% (w/v) in 1x TAE buffer (40 mM Trizma, 4.7% acetic acid, 50 
mM EDTA pH 8.0) and 1.5 µg/ml ethidium bromide (Sigma). The electrophoresis was 
carried out at 80 V and the DNA was then visualized under ultraviolet (UV) light. 
 
3.2.3 Restriction endonuclease reactions 
 Expression plasmids and PCR fragments were submitted to restriction 
endonuclease reaction, according to their restriction sites. The plasmids were 
digested by NcoI – KpnI, human α-actinin DNA fragments were digested by BsaI – 
KpnI and the PDZ domain of ZASP was digested by NcoI – KpnI (Table 3.1). 
Restriction enzymes and buffers were purchased from New England BioLabs and the 
reaction was performed following the manufacturer’s instructions. 
 
3.2.4 DNA purification 
 The linearized plasmids and PCR fragments were purified from the agarose 
gel using the QIAGEN QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions. 
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Figure 3.1 Representation of the human α-actinin isoform 2 and E. histolytica α-actinin isoform 2 
constructs used in this study for protein expression. The constructs of human α-actinin isoform 1 were 
designed based on the sequence alignment between these two isoforms (1 and 2). A) 2AFL, B) 
2AFLY, C) 2hd, D) 2ABDY, E) 2ABDa, F) 2ABDa_SR1, G) 2SR4_CaM, H) 2CaM, I) 2EF-3/4, J) 2Eh. 
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Table 3.1 Oligonucleotides and Tm (°C). Restriction sites are highlighted in red for NcoI, in green for 
BsaI and in purple for KpnI. 
 
FRAGMENT OLIGONUCLEOTIDES (5’ to 3’) Tm (°C) 
1ABDa_SR1_FOR 
1ABDa_SR1_REV 
AATTTGGTCTCCCATGGCCTGGGAGAAGCAGCAG 
AAAAGGTACCTTATTATTAATTCAGCAACCACTCCTCATAGC 
75.5 
66.9 
2ABDa_SR1_FOR 
2ABDa_SR1_REV 
AATTTGGTCTCCCATGGGCTGGGAGAAGCAGCAG 
AAAAGGTACCTTATTAATTGAGCAACCACTCCTCGTAAC 
75.5 
66.5 
1SR4_CaM_FOR 
1SR4_CaM_REV 
CATGCCATGGCCACAATGAGAGGCTACGCAAGC 
AAAAGGTACCCTAGAGGTCACTCTCGCCG 
71.9 
65.2 
2SR4_CaM_FOR 
2SR4_CaM_REV 
AATTTGGTCTCCCATGGGCAACGAGCGTCTGAGGCGCC 
AAAAGGTACCTCACAGATCGCTCTCCCCG 
82.2 
67.4 
1CAM_FOR 
1CAM_REV 
AATTTGGTCTCCCATGGAGCCAGGAGCAGATGAATGAGTTC 
AAAAGGTACCCTAGAGGTCACTCTCGCCG 
82.1 
65.2 
2CAM_FOR 
2CAM_REV 
AATTTGGTCTCCCATGGACCCAGGAGCAGATGAATGAGTTC 
AAAAGGTACCTCACAGATCGCTCTCCCCG 
82.1 
67.4 
1EF-3/4_FOR 
1EF-3/4_REV 
AATTTGGTCTCCCATGGCCGACACAGATACAGCAGACC 
AAAAGGTACCCTAGAGGTCACTCTCGCCG 
83.2 
65.2 
2EF-3/4_FOR 
2EF-3/4_REV 
AATTT GGTCTCCCATGGACACCGACACTGCCGAGCAGG 
AAAAGGTACCTCACAGATCGCTCTCCCCG 
87.2 
67.4 
2ABDa_FOR 
2ABDa_REV 
AATTTGGTCTCCCATGGGCTGGGAGAAGCAGCAG 
AAAAGGTACCTTATTAAGCCGCTGTCTCGGCC 
75.5 
75.8 
2ABDY_FOR 
2ABDY_REV 
AATTTGGTCTCCCATGGGCTACATGATCCAGGAGGAGG 
AAAAGGTACCTTATTAAGCCGCTGTCTCGGCC 
82.7 
75.8 
2AFLY_FOR 
2AFLY_REV 
AATTTGGTCTCCCATGGGCTACATGATCCAGGAGGAGG 
AAAAGGTACCTCACAGATCGCTCTCCCCG 
82.7 
67.4 
∆2ABDa R163E_FOR 
∆2ABDa R163E_REV 
GGTCTGCTGCTTTGGTGTCAGgaaAAAACTGCTCCTTATAGAAAT 
ATTTCTATAAGGAGCAGTTTTttcCTGACACCAAAGCAGCAGACC 
81 
81 
∆2ABDa R169E_FOR 
∆2ABDa R169E_REV 
CAGAGGAAAACTGCTCCTTATgaAAATGTGAACATTCAGAACTTC 
GAAGTTCTGAATGTTCACATTttcATAAGGAGCAGTTTTCCTCTG 
78 
78 
∆2ABDa R192E_FOR 
∆2ABDa R192E_REV 
GGACTCTGTGCCCTCATCCACgaACACCGGCCTGACCTCATTGAC 
GTCAATGAGGTCAGGCCGGTGttcGTGGATGAGGGCACAGAGTCC 
86 
86 
∆2AFL E23A/ E24A/ E25A_FOR 
∆2AFL E23A/ E24A/ E25A_REV 
GATGAGTACATGATCCAGgcggcggcgTGGGACCGCGACCTGCTC 
GAGCAGGTCGCGGTCCCAcgccgccgcCTGGATCATGTACTCATC 
94.1 
94.1 
∆2AFL E149A/E150A_FOW 
∆2AFL E149A/E150A_REV 
CTATTCAGGATATTTCGGTTgcggcgACATCTGCCAAAGAAGGTC 
ACCTTCTTTGGCAGATGTcgccgcAACCGAAATATCCTGAATAG 
84.6 
84.6 
∆2AFL E260A/Q261A/E263A_FOW 
∆2AFL E260A/Q261A/E263A_REV 
GCTTTTGCGGGCGCGgcggcgGCCgcgACAGCGGCTAACAGG 
CCTGTTAGCCGCTGTcgcGGCcgccgcCGCGCCCGCAAAAGC 
98.3 
98.3 
∆2AFL E310A/ K311A_FOR 
∆2AFL E310A/ K311A_REV 
CTGGAGAACCGGACTCCCgcggcgACCATGCAAGCCATGCAG 
CTGCATGGCTTGCATGGTcgccgcGGGAGTCCGGTTCTCCAG 
94.1 
94.1 
PDZ_FOR 
PDZ_REV 
CATGCCATGGCTTACAGTGTGACCCTG 
TTGGTACCTTACTTTGATTTCTGCAGGGTG 
76 
71.9 
_________________________________________________MATERIALS AND METHODS 
24 
 
3.2.5 Cloning into expression plasmids 
 The expression plasmids used in this study were based on the pETM 
expression system. These vectors were designed to produce a fused tag at the N-
terminal region of the protein. The tags can be polyhistidine-tag (6x His-tag), 
glutathione S-transferase-tag (GST) or other proteins, such as E. coli thioredoxin A 
(TrxA) and disulfide oxidoreductase A (DsbA), fused to the target protein to improve 
its solubility. The match between tag and vector is listed in Table 3.2. 
 After the restriction endonuclease reaction, linearized plasmids and target 
fragments were submitted to ligation reaction with the T4 ligase enzyme and buffer 
purchased from Fermentas. The reaction followed the manufacturer’s instructions. 
 
Table 3.2 Expression plasmids and fused tags expressed with the proteins. 
 
PLASMID N-TERMINAL TAG 
pETM13 No tag 
pETM11 6x His-tag 
pETM13 GST 6x His-tag + GST-tag 
pETM20 6x His-tag + TrxA  
pETM13dsbAGSHISTEV 6x His-tag + DsbA 
 
3.2.6 Competent cells transformation 
 The ligation products were transformed into chemical competent strain 
Escherichia coli DH5α (cloning strain; Table 3.3). The transformation was done by 
the heating shock method where 10 µl of the ligation mixture were added to 50 µl of 
competent cells. After 20 min of incubation on ice, these cells were subsequently 
heated shock at 42° C during 30 sec and cooled on ice for another 5 min. After this 
thermal shock, 400 µl of Luria Broth (LB, Sigma) were added and the resulting 
mixture incubated at 37° C and 120 rpm for 1 h, to allow the cells to recover from the 
shock. 
 The same protocol was used to transform positively selected plasmids into 
expression strains: E. coli BL21 (DE3), BL21 (DE3) pLysS, BL21 (DE3) Rosetta 
pLysS and BL21 (DE3) Star (Table 3.3). 
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Table 3.3 E. coli strains and their genetic background [Stratagene, Novagen, (Hanahan, 1983)]. 
 
E. coli STRAINS GENOTYPE 
DH5α supE44 ∆lacU169 (Ф80 lacZ ∆M15) hsdR17 recA1 
endA1 gyrA96 thi-1 relA1 
BL21 (DE3) E. coli B F- ompT hsdSB(rB-mB-) gal dcm λ(DE3) 
BL21 (DE3) pLysS E. coli B F
- ompT hsdSB(rB-mB-) gal dcm λ(DE3) 
pLysS (CmR) 
BL21 (DE3) Rosetta pLysS E. coli B F
- ompT hsdSB(rB-mB-) gal dcm lacY1 
λ(DE3) pLysS pRARE2 (CmR)  
BL21 (DE3) Star E. coli B F
- ompT hsdSB(rB-mB-) gal dcm λ(DE3) 
rne131 
 
3.2.6.1 Co-transformation experiments 
 Plasmids containing the human α-actinin N-terminal (ABD_SR1, Construct A, 
Table 4.2) and C-terminal (CaM or EF-3/4, Construct B, Table 4.2) fragments desired 
for a complex formation (positively selected by antibiotics, colony PCR and DNA 
sequencing) were mixed together in a concentration ratio of 1:1 and transformed into 
expression strains for further co-expression experiments and protein-protein complex 
formation. 
 
3.2.7 Selection of positive clones using antibiotics 
 The transformation products were plated into LB-agar medium (LB + 1.5% 
agar) containing the appropriated antibiotic: ampicillin (100 µg/ml), kanamicin (100 
µg/ml) or chloramphenicol (34 µg/ml), depending on the plasmid and the E. coli strain 
in study (Table 3.4). The plate was incubated over night at 37° C. 
 
3.2.8 Plasmid extraction in mini scale (miniprep) 
 After the selection of positive clones by antibiotics and colony PCR, these 
colonies were submitted to miniprep using the QIAprep Spin Miniprep Kit (QIAGEN) 
according to the manufacturer’s instructions. 
 
3.2.9 DNA sequencing 
 The extracted plasmids from E. coli DH5α were sent to DNA sequencing at 
VBC-Biotech Service GmbH, Vienna, Austria. The oligonucleotides used for 
sequencing were complementary to T7 promoter or T7 terminator. 
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Table 3.4 Antibiotics used for selection of positive clones. 
 
ANTIBIOTIC STRAINS AND PLASMIDS 
Ampicillin E. coli DH5α, BL21 (DE3) and BL21 (DE3) Star transformed with pETM20, pET8C and pET19b 
Kanamicin 
E. coli DH5α, BL21 (DE3) and BL21 (DE3) Star 
transformed with pETM11, pETM13, pETM13 GST 
and pETM13dsbAGSHISTEV 
Ampicillin + Kanamicin (for 
co-transformation assays) 
E. coli BL21 (DE3) and BL21 (DE3) Star transformed 
with pETM20 + pETM11, pETM13, pETM13 GST and 
pETM13dsbAGSHISTEV 
Ampicillin + Kanamicin + 
Chloramphenicol (for co-
transformation assays) 
E. coli BL21 (DE3) pLysS, BL21 (DE3) Rosetta pLysS 
transformed with pETM20 + pETM11, pETM13, 
pETM13 GST and pETM13dsbAGSHISTEV 
Kanamicin + 
Chloramphenicol 
E. coli BL21 (DE3) pLysS, BL21 (DE3) Rosetta pLysS 
transformed with pETM11, pETM13, pETM13 GST 
and pETM13dsbAGSHISTEV 
Ampicillin + 
Chloramphenicol 
E. coli BL21 (DE3) pLysS, BL21 (DE3) Rosetta pLysS 
transformed with pETM20, pET8C and pET19b 
 
3.3 Protein manipulation 
3.3.1 Over-expression of recombinant proteins 
 After checking the sequence identity of the cloned inserts, the plasmids were 
then transformed into expression strains and plated into LB-agar with appropriated 
antibiotics. 
 A single colony was used for LB pre-culture. The pre-culture of the target 
protein grown over night at 37° C and 120 rpm was diluted in fresh LB containing the 
appropriated antibiotics. For small scale over-expression experiments, 0.4 ml of pre-
culture was diluted in 10 ml LB while for large scale; 8 ml of pre-culture was diluted in 
1 l LB, always with appropriated antibiotics.  
 The fresh culture grew at 37° C and 120 rpm until it reached an optical density 
OD600 between 0.6 and 0.8. The proteins were subsequently induced by adding 0.5 
µM IPTG (Sigma). Protein induction lasted 4 h for experiments performed at 37° C or 
over night for experiments performed at 20° C. After this period the culture was 
harvested by centrifugation (6.000 rpm, 15 min, at 4° C). 
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3.3.1.1 Small scale overexpression 
 Lysis of the induced cells derived from the small scale over-expression 
experiments was done using the Bug buster Protein Extraction Reagent (Novagen), 
following the manufacturer’s instructions. 
 
3.3.2 Purification of recombinant proteins 
 In order to obtain pure protein the induced cells were resuspended in lysis 
buffer (20 ml lysis buffer per litre of culture: 20 mM Tris-HCl pH 7.6, 150 mM NaCl, 10 
mM imidazole, supplied with protease inhibitor if necessary; Complete Mini EDTA-
Free, Roche) and then disrupted by 10 min sonication on ice with 40% maximum 
energy output (Bandelin Sonoplus). The cell lysate was clarified by centrifugation 
(20.000 rpm, 30 min, at 4° C). 
 The supernatant resulting from the centrifuged lysate was submitted to three 
different protein purification steps including gravity flow IMAC, ion exchange and size 
exclusion chromatography (SEC). 
 The resin Ni sepharose 6 Fast Flow (GE Healthcare Life Sciences) charged 
with 0.1 M NiSO4 was used for gravity flow IMAC. The cell lysate supernatant was 
poured into a gravity His-trap column (Bio-Rad) previously equilibrated with the lysis 
buffer. After the supernatant had passed through the column, 6 column volumes of 
the same buffer was used to wash it. Then, the protein was eluted from the column 
by the IMAC elution buffer (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 300 mM 
imidazole). 
 The next protein purification step was the ion exchange chromatography using 
a Resource Q column (Amershan Biosciences) and an Äkta purifier system (GE 
Healthcare Life Sciences). The column was equilibrated with buffer A (50 mM Tris-
HCl pH 7.6, 50 mM NaCl) and the protein was eluted from the column with buffer B 
(50 mM Tris-HCl pH 7.6, 2 M NaCl) in a linear gradient. 
 The last purification step by size exclusion chromatography was also 
performed in an Äkta purifier system (GE Healthcare Life Sciences) using 
Superdex200 or Superdex75 HiLoad 26/60 columns [depending on the molecular 
weight (MW) of the molecule; Amershan Biosciences] equilibrated with appropriated 
buffer (section 4.3). 
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3.3.2.1 Purification of human α-actinin half dimer (hd) 
 The purification of human α-actinin hd is considerably different from that of the 
other constructs. The dimmer is formed (Figure 4.9A) during the protein expression 
and purified very tightly, with high level of purity, during the gravity flow IMAC since 
half of the molecule is His-tagged (6x His – SR3_SR4_CaM, ~40 kDa), while the 
other half remains not tagged (ABD_SR1_SR2, ~60 kDa). 
 
3.3.2.2 Co-purification experiments 
 The induced cells containing the α-actinin target inserts for complex formation 
were broken together by sonication and after centrifugation the supernatant was 
submitted to gravity flow IMAC. 
 To form the complex of 2hd and PDZ domain of ZASP cells with both 
recombinant proteins over-expressed were mixed and broken together by sonication. 
After centrifugation the supernatant was submitted to gravity flow IMAC followed by 
size exclusion chromatography using the column Superdex200 HiLoad 26/60 
(Amershan Biosciences), equilibrated with 20 mM Tris-HCl pH 7.6, 150 mM NaCl. 
 
3.3.2.3 Analytical size exclusion chromatography 
 Analytical size exclusion chromatography was employed in order to analyse 
the formation of the α-actinin 2hd and the PDZ domain complex in the presence and 
absence of lysophosphatidic acid (LPA). An analytical Superdex200 10/300 GL 
column (Amershan Biosciences) was used, previously equilibrated with 20 mM Tris-
HCl pH 7.6, 150 mM NaCl. 
 As a control, the two proteins were mixed in a molar ratio of 1:1 incubated 1 h 
at 4° C and centrifuged (18.000 rpm, 15 min, at 4° C) before analytical size exclusion 
chromatography. To verify whether LPA would enhance the complex formation, LPA 
was added to the protein-protein sample in a molar ratio between 2hd, PDZ and LPA 
of 1:1:1, 1:1:3 and 1:1:5. 
 
3.3.3 Tag cleavage by Tobacco etch virus (TEV) protease 
 In order to cleave the tag from the protein, TEV protease was added to the 
target protein sample, which has been purified once by gravity flow IMAC, in an 
OD280 ratio 1:50. This mixture was dialyzed over night against TEV cleavage buffer 
(50 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA, 2 mM ß-mercaptoethanol) at 4° 
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C. After cleavage, the sample was resubmitted to gravity flow IMAC, to eliminate any 
uncleaved protein, TEV and free tag. The cleaved target protein was subsequently 
submitted to further purification steps. 
 
3.3.4 Protein dialysis 
 Protein dialysis was carried out in Spectra/Por Dialysis Membrane Tubing with 
molecular weight cut off (MWCO) between 12.000 Da and 14.000 Da (Spectrum 
laboratories Inc.) against appropriated buffer. 
 
3.3.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 Protein samples were analysed under denaturing conditions in polyacrylamide 
gel according to their MW. The protocol followed Laemmli’s method (Laemmli, 1970). 
The protein bands were visualized by coomassie blue staining. 
 
3.3.6 Protein concentration 
 Concentration of the protein was done by centrifugation using Centriprep 
centrifugal filters devices with regenerated cellulose membranes and cut off of 50, 30 
or 10 (Millipore), depending on the size of the molecule. The protocol followed the 
manufacturer’s instructions. 
 
3.3.7 Protein concentration determination 
 The protein concentration was determined by spectroscopy, measuring the 
absorbance of the protein by UV at 280 nm (OD280; Nanophotometer, IMPLEN). The 
protein concentration was calculated by the equation: 
Protein concentration (mg/ml) = OD280 x dilution / extinction coefficient (g/l) 
 The extinction coefficient (ε) was calculated based on the primary sequence of 
each construct by the ProtParam tool found in the ExPASy proteomics website 
(http://www.expasy.ch/). 
 
3.3.9 Protein storage 
 Purified proteins were stored by flash-freezing in liquid nitrogen and 
subsequently kept at - 80° C. 
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3.3.10 Differential scanning fluorimetry (DSF) 
 DSF was employed to screen an optimal buffer for protein stability. The 
temperature of the protein unfolding is monitored via the rise in the dye SYPRO 
Orange (Invitrogen) fluorescence signal while binding to hydrophobic patches of the 
protein that become accessible during the heating process (20° C to 95° C). The 
more stable a protein in a given condition is, the later it will start to unfold and the 
higher the melting temperature (Tm) will be (Ericsson et al., 2006). 
 Screens with 24 different conditions of buffers, in different range of pH and ion 
strength were prepared in a 96-well plate with 4x repetition to avoid pipetting errors. 
 The reaction was performed in a final volume of 25 µl: 12.5 µl buffer, 5 µl 
protein (~1 mg/ml) and 7.5 µl dye diluted 1/1000. The experiments were carried out in 
several Real-Time PCR machines with filters calibrated to absorb signals from the 
SYPRO Orange dye: Mx3005 Real-Time QPCR System (Stratagene), Mastercycler 
eprealplex (Eppendorf) and iQ5 multicolour Real-Time PCR Detection System (Bio-
Rad). 
 
3.3.10.1 Binding of inositol hexakisphosphate (IP6) to ABD 
 DSF was also applied to study the binding of inositol hexakisphosphate (IP6) 
to 2ABDa WT. The measurements were performed with different concentrations of 
IP6 diluted in 20 mM PIPES pH 7.5, 100 mM NaCl. The IP6 concentrations ranged 
from 0.02 mM to 1.5 mM and the final reaction volume was set to 15 µl: 7.5 µl protein 
(~60 µM) and 4.5 µl dye diluted 1/1000. 
 
3.3.11 Dynamic light scattering (DLS) 
 DLS was used to evaluate the purity of a given protein sample before setting 
up crystallization trials. In this technique the hydrodynamic diameter of particles in 
solution is measured under a monochromatic light (laser) beam. The particles in 
Brownian motion in solution cause fluctuations in the scattered light intensity 
according to their composition. Protein solution in different oligomerization states 
(aggregates, monomers, dimers, etc) scatter light in a variety of intensities measured 
by a detector placed at a 90° angle to the incident laser light. Sample purity can 
therefore be measured according to its population (Borgstahl, 2007). It is believed 
that monodisperse samples (> 80%) are more likely to crystallize (D'Arcy, 1994). 
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 DLS measurements were made in a DynaPro-801 instrument (Protein 
Solutions Inc.) at 22° C with 100 acquisitions taken at 1 s intervals each one. Data 
analysis was performed using the Dynamics V6 software (Protein Solutions Inc.). 
 
3.3.12 Protein reductive methylation 
 Protein reductive methylation is a chemical modification method employed to 
alter the crystallization properties of the protein. This chemical modification generates 
changes in the surface charges of the protein that could enhance the crystal packing 
potential of the protein during the crystallization process. This change of surface 
charges occurs because primary free amino groups found in lysine residues (K) or in 
the N-terminal of the protein can be changed to secondary amino groups or tertiary 
amino groups (Figure 3.2). 
 The methylation protocol was established by Thomas S. Walter and co-
workers (Walter et al., 2006). However, all samples submitted to methylation were 
previously purified (section 3.13) and subsequently dialyzed against the methylation 
buffer (50 mM HEPES pH 7.5, 250 mM NaCl). After the methylation process, the 
samples were re-purified through size exclusion chromatography with the 
appropriated buffer (section 4.3). 
 
 
 
Figure 3.2 Different amino groups: primary (found in K or N-terminal region of proteins), secondary 
and tertiary. 
 
3.3.13 Surface entropy reduction (SER) mutations  
 SER is a method that can enhance the crystallizability of a protein by reducing 
the phase transition energy barrier. This reduction occurs when cluster of surface 
residues with high conformational entropy are mutated to residues with lower ones, 
e.g. mutation of glutamate (E), lysine (K) or arginine (Q) to alanine [A;(Derewenda, 
2004a)]. 
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 Since α-actinin is a recalcitrant protein to crystallization, the 2AFL construct 
was submitted to SER mutations. The choice of clusters to be mutated was done 
using the web service http://nihserver.mbi.ucla.edu/SER/ which takes into account 
the entropy of the residues within a continuous stretch, predicted secondary structure 
and sequence conservation (Goldschmidt et al., 2007). 
 The website generated double-site and triple-site mutation clusters. The 
mutations were done using the Site-directed Mutagenesis Kit (Qiagen) and specific 
oligonucleotides (Table 3.1) following the manufacturer’s instructions. The mutation 
sites were validated by DNA sequencing. 
 
3.3.14 Characterization of ABD mutants 
3.3.14.1 Mutants 
 Single-site mutants were designed to validate the proposed 
phosphatidylinositol (4, 5)-biphosphate (PiP2) binding site within the ABD of α-actinin 
(Franzot et al., 2005). It has been suggested that this binding site is formed by 
arginine residues R163, R169 and R192 (numbering according to human α-actinin 
isoform 2). 
 The single R residues were mutated to glutamate (E) using the Site-directed 
Mutagenesis Kit (Qiagen) and specific oligonucleotides (Table 3.1) following the 
manufacturer’s instructions. The mutation site was validated by DNA sequencing. 
 
3.3.14.2 PiP strips 
 In order to study the binding of α-actinin 2ABDa WT and its mutants to 
different types of phosphoinositide [phosphatidylinositol (PtdIns), phosphatidylinositol 
3-phosphate (PtdIns(3)P), phosphatidylinositol 4-phosphate (PtdIns(4)P), 
phosphatidylinositol 5-phosphate (PtdIns(5)P), phosphatidylinositol 3,5-biphosphate 
(PtdIns(3,5)P2), phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2), 
phosphatidylinositol 3,4-biphosphate (PtdIns(3,4)P2), phosphatidylinositol 3,4,5-
triphosphate (PtdIns(3,4,5)P3)], the proteins were submitted to PiP strips membrane 
binding method. The negative control was the protein chlorite dismutase (kindly 
provided by Julius Kostan). PiP strips were purchased from Echelon Biosciences Inc. 
and the protocol was according to the manufacturer’s instructions. 
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3.3.14.3 Isothermal titration calorimetry (ITC) 
 ITC was used to study the binding of α-actinin 2ABDa WT and mutants to 
inositol triphosphate (IP3; Sigma). It is a technique used to study molecular 
interactions and can provide information such as stoichiometry (n), binding affinity 
(Ka), heat of binding (∆H), entropy (∆S), free energy (∆G) and dissociation constant 
(Kd; which is the inverse of the Ka). The principle of ITC is based on measurements of 
the heat released or absorbed when a protein is titrated with a hypothetical ligand. Its 
signal depends on the protein and ligand concentrations, the cell volume, the injected 
volume and the values of n, Ka and ∆H (Lewis and Murphy, 2005). 
 Titration of 2.5 mM IP3 into solutions of 266 µM 2ABDa WT, 116 µM ∆2ABDa 
R169E and 379 µM ∆2ABDa R192E was carried out at 25° C in a VP-ITC 
Microcalorimeter (MicroCal). The IP3 was titrated using a 250 µl rotating syringe into 
a sample cell containing the given sample. One initial injection of 2 µl was followed 
by 29 injections of 10 µl. 
 IP3 was dissolved to suitable concentration into the buffer used for protein 
dialysis (20 mM Na citrate pH 7.0, 100 mM NaCl) and all samples were degassed 
prior the experiment. 
 Data analysis was performed using the ORIGIN version 7 software (MicroCal) 
by peak integration and the binding data were fitted to the "one sites" model. 
 
3.3.14.4 Circular dichroism (CD) 
 Near-UV CD was performed to gain information about conformational changes 
of 2ABDa WT upon binding of IP6 [Sigma; reviewed by (Kelly and Price, 2000)]. CD 
measurements were carried out on an Applied Photophysics PiStar-180 
spectrometer, using a 1 mm path length quartz cell (Hella). Near-UV CD signals 
between 240nm and 360nm were measured for 2ABDa WT and 2ABDa WT with a 
tenfold excess of IP6 in 20 mM PIPES pH 7.5, 100 mM NaCl. Data was collected at 
25° C, with a step size of 1 nm. 
 
3.3.14.5 Nuclear magnetic resonance spectroscopy (NMR) 
 In order to study the binding of 2ABDa WT to IP3, the sample was submitted 
to 2D-NMR and selective T1 measurement. The experiments were carried out and 
analysed by Dr. Bettina Schweng (Department of Biomolecular Structural Chemistry, 
University of Vienna). 
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A) 15N – labelling of ABD 
 To carry out the 2D-NMR experiments, the protein was 15N-labelled using the 
following protocol: a pre-culture with E. coli (DE3) Rosetta pLysS carrying the ABDa 
WT insert cloned into pETM11 was grown in LB medium over night at 37° C. 8 ml of 
this pre-culture were diluted in 1 l of M9 minimal medium [6 g Na2HPO4, 3 g KH2PO4, 
0.5 g NaCl diluted in 1 l Milli-Q water, followed by autoclaving. Prior to use, 2 ml of 1 
M MgSO4 and 20 ml of 20% D-glucose-13C6 (ISOTEC) were added] containing 1 g 
ammonium-15N chloride, 98 + atom% 15N (15NH4Cl; ISOTEC) and appropriate 
antibiotics (Table 3.3). When an OD600 around 0.6 was reached, the temperature was 
decreased from 37° C to 20° C and the protein was induced over night by 0.5 µM 
IPTG. 
 
B) Two-dimensional NMR 
 2D-NMR experiments were performed with 1 mM 2ABDa WT 15N-labelled and 
IP3 in different concentration ratios, ranging from 1:1 to 1:6. Experiments were 
performed at 25° C in a Varian Unity 800 MHz spectrometer (Varian). 
 
C) Selective T1 measurement 
 Selective T1 measurement was applied to study IP3 and non-labelled 2ABDa 
WT binding and the experiments were performed at 25° C in a Varian Unity 600 MHz 
spectrometer (Varian). In this experiment 100 µM IP3 were added to 10 µM 2ABDa 
WT and the measurement done. 
 
3.3.15 Protein crystallization experiments 
 Pure protein solutions at different concentrations were submitted to 
crystallization trials with or without N-terminal 6x His-tag. Concentrations used were 
evaluated using the Pre-Crystallization Test kit (PCT, Hampton Research) following 
the manufacturer’s instructions. Initial crystallization conditions were screened at 22° 
C using commercial screens such as Grid screen, PEG/Ion screen, Index 1-2 and 
Crystal screen 1-2 from Hampton Research; JBS 1-10 from JenaBioscence; Wizard 
1-2 and Cryo1-2 from Emerald Biostructures; JSCG+ Suite and PACT Suite from 
QIAGEN. These initial screenings were performed by robot assisted nano-drop 
vapour diffusion (Cartesian, Zinsser Analytic or Phoenix, Rigaku) in drops formed 
with condition and protein solutions ratio of 1:1 and 1:2 (v/v). 
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 The optimization of crystallization conditions was performed manually with 
sitting or hanging drop vapour diffusion methods at different temperatures (22° C, 14° 
C and 4° C) and by grid screen, altering the buffer pH and precipitant concentration. 
Drops had volume ratio mother liquor to protein solution of 1:1 or 1:2, depending on 
the construct. Crystal hits were obtained in times varying from a few days to several 
months, also depending on the construct. 
 Once the best crystallization condition was found, the additive screen 
(Hampton Research) was used following the manufacturer’s instructions. 
 
3.3.15.1 ABDY soaking and co-crystallization 
 In order to check the PIP2 binding site within α-actinin ABD, diffraction-quality 
crystals from 2ABDY were soaked with IP3 or IP6. Co-crystallization experiments 
with IP3 were also attempted. 
 Soaking was done adding different concentrations of IP3 or IP6 to the cryo-
solution. The cryo-solution was obtained adding PEG [25% to 30% (v/v)] to the 
mother liquor and the MW of the PEG was dependent on the mother liquor. The 
concentration of IP3 or IP6 used ranged from 10 mM to 15 mM (final concentration). 
Different soaking times ranged from 1 to 40 min. 
 The co-crystallization was done by adding 5 mM of IP3 to the protein sample 
(10 mg/ml). The mixture was incubated (at 30° C, 30 min) and centrifuged (20.000 
rpm, 20 min, at 4° C). Subsequently, it was submitted to crystallization trials. 
 
3.3.16 Data collection 
 Crystals used for data collection were soaked briefly in cryo-solution and then 
flash-frozen in liquid nitrogen or directly in the cryostream. Data were collected at 100 
K using an ADSC Q315 detector at the ESRF beamline ID23-1 and the MAR225 
detector at the ESRF beamline ID23-2. 
 The X-ray Detector Software program package [XDS; (Kabsch, 1993)] was 
used for processing the collected data. The diffraction images were displayed and the 
pictures were made by the ADXV software. 
 
3.3.17 Structural determination, model building, refinement and validation 
 All ABD structures were solved by the molecular replacement (MR) method 
(Rossmann, 1990; Rossmann and Blow, 1962) using the program MOLREP (Vagin 
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and Teplyakov, 1997) , part of the Collaborative Computational Project No. 4 (CCP4). 
The model used as search model was the structure of human α-actinin ABD isoform 
3 [PDB entry 1WKU; (Franzot et al., 2005)], excluding the water molecules. 
 Refinement of the structures was performed using REFMAC5 (Murshudov et 
al., 1997), also from CCP4. Model building was done using the program 
Crystallographic Object-Oriented Toolkit [Coot; (Emsley and Cowtan, 2004)]. 
 Structure validation was done using the MolProbity web service 
http://molprobity.biochem.duke.edu/ (Davis et al., 2004) and the molecule was 
visualized using the PyMOL molecular viewer software (DeLano Scientific LLC). 
 
3.3.18 Small angle x-ray scattering (SAXS) 
 SAXS was used to study conformational changes in the N-terminal or C-
terminal regions of α-actinin in the presence of Ca2+ ions. The scattering patterns of 
α-actinin 2Eh, human AFL and hd of both isoforms (1 and 2) were measured at 
solute concentrations ranging from 0.5 mg/ml to 6.0 mg/ml. Isoform 1 and Eh2 
constructs were purified in standard buffer in the presence and absence of 2 mM 
CaCl2, while the constructs for isoform 2 were purified only with standard buffer (20 
mM Tris-HCl pH 7.6, 150 mM NaCl). Sample purity was verified by DLS before the 
SAXS measurements.  
 Data were collected on beamline X33 at the DORIS storage ring of DESY 
(Hamburg) using a MAR345 image plate detector and analysed by the collaborators, 
Dr. Dmitri Svergun and Dr. Peter Konarev (EMBL-Hamburg outstation). The forward 
scattering I(0) and the radius of gyration (Rg) were evaluated using the Guinier 
approximation, by the program GNOM (Svergun, 1992). The low resolution shape 
analysis of the SAXS data was done ab initio using the program DAMMIN (Svergun, 
1999). 
 The low resolution molecular envelope was fit with the structure of individual 
domains by rigid body modelling using the software BUNCH (Petoukhov and 
Svergun, 2005). 
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4. RESULTS 
 
4.1 Constructs, gene amplification and selection 
4.1.1 α-actinin 
 DNA fragments for the constructs listed in Table 4.1 were amplified by PCR, 
except for human α-actinin full length (AFL) and half dimer (hd), kindly provided by 
Dr. Jari Ylänne. Isoform 2 of Entamoeba histolytica α-actinin (2Eh) was cloned by the 
collaborators (Dr. Lars Backman). 
 The PCR products were of expected sizes (Figure 4.1) and were cloned into 
expression vectors listed in Table 4.1. Positive clones were subsequently selected 
through colony PCR and DNA sequencing. 
 
 
 
Figure 4.1 PCR products of human α-actinin obtained using the full length construct as a template and 
specific oligonucleotides (Table 3.1). DNA samples were resolved by 1% agarose gel. A) Column 1- 
DNA marker (kb), 2- CaM (435 pb) and 3- EF-3/4 (218 pb). B) Column 1- DNA marker (kb), 2- CaM 
(435 pb), 3- ABDa_SR1 (1070 pb), 4- SR4_CaM (800 pb), 5- 2ABDa (800 pb), 6- 2ABDY (780 pb) and 
7- ∆2AFLY (2600 pb). 
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Table 4.1 α-Actinin constructs designed for this project, expression vectors used for cloning and 
respective protein molecular weight (MW). Numbers in front of constructs abbreviations refer to α-
actinin isoform in context (human isoforms: 1 = non-muscle or 2 = muscle). Y means that the construct 
starts at tyrosine residue 19 and a; the construct starts at the ABD. 
 
Construct Vector MW (kDa) 
1, 2ABDa_SR1 pETM13dsbAGSHISTEV 61 
2SR4_CaM pETM13dsbAGSHISTEV 50 
1, 2ABDa_SR1 pETM20 57 
1SR4_CaM pETM20 46 
1, 2CaM pETM20 33 
1, 2CaM pETM13 GST 43 
1, 2EF-3/4 pETM13 GST 34 
1SR4_CaM pETM13 GST 46 
1, 2SR4_CaM pETM13 30 
1, 2CaM pETM13 17 
1, 2EF-3/4 pETM13 8 
2SR4_CaM pETM11 32 
2ABDa_SR1 pETM11 43 
2CaM pETM11 18 
2ABDa pETM20  42 
2ABDa pETM13 GST 52 
2ABDa pETM11 27 
∆2ABDa R169E pETM11 27 
∆2ABDa R192E pETM11 27 
2ABDY pETM11 31 
∆2AFL E23/ E24/ E25A pET8C  105 
∆2AFL E310/ K311A pET8C  105 
∆2AFLY (E310/ K311A) pETM11 103 
1, 2AFL (WT) pET8C 105 
1, 2hd 
(ABD_SR1_SR2//SR3_SR4_CaM) pET8C 60 + 40 
2Eh pET19b 73.5 
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4.1.2 PDZ domain of ZASP 
 PDZ domain fragment was amplified by PCR (Figure 4.2) and cloned into 
expression vectors such as pETM13 GST and pETM13dsbAGSHISTEV (Table 3.2). 
Positive clones were then selected through colony PCR and DNA sequencing. 
 
 
 
Figure 4.2 PCR product of the PDZ domain obtained using ZASP full length as a template and 
specific oligonucleotides (Table 3.1). DNA sample was resolved by 1% agarose gel. Column 1- DNA 
marker (kb) and 2- PDZ (430 pb). 
 
4.2 Over-expression of recombinant proteins 
4.2.1 Expression of AFL, 2Eh, hd, ABD and PDZ domain of ZASP 
 Over-expression of proteins AFL, 2Eh, hd, ABD (Figure 3.1) and PDZ was 
checked by SDS-PAGE. Since they were in the soluble fraction of the cell lysate they 
were submitted to purification steps. 
 
4.2.2 Co-expression systems for α-actinin 
 With the objective of obtaining the complex of different domains of α-actinin 
(ABD_SR1 with CaM or EF-3/4; Figure 3.1), plasmids containing the α-actinin 
desired inserts were co-transformed in different E. coli strains (Table 4.2). The 
protein overexpression was checked by SDS-PAGE (Figure 4.3). 
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Figure 4.3 15% SDS-PAGE of small scale co-expression experiments of human α-actinin ABDa_SR1 
+ SR4_CaM or CaM or EF-3/4 of both isoforms (1 and 2) at 37° C. Different constructs and E. coli 
strains are described at Table 4.2. The strains are also indicated under the gel. S is an abbreviation to 
soluble fraction of cell lysate, while P stands for pellet (insoluble fraction of the cell lysate). 
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Table 4.2 Co-transformation constructs and E. coli strains for over-expression experiments. Last 
column named “Figure 4.3” relates the co-expression results showed at Figure 4.3 to their respective 
constructs and strain. 
 
Construct A Construct B Strains Figure 4.3 
1ABDa_SR1 
pETM20 
(His-tag + TrxA) 
57kDa 
1SR4_CaM 
pETM13 
(GST-tag) 
45kDa 
BL21 (DE3) 1 
BL21 (DE3) pLysS 2 
BL21 (DE3)Rosetta pLysS 3 
BL21 (DE3) Star 4 
1SR4_CaM 
pETM13 
(no tag) 
30kDa 
BL21 (DE3)  5 
BL21 (DE3) pLysS 6 
BL21 (DE3) Rosetta pLysS 7 
BL21 (DE3) Star 8 
1CaM          42kDa 
pETM13 (GST-
tag) 
BL21 (DE3) 20 
BL21 (DE3) Rosetta pLysS 21 
1EF-3/4       34kDa 
pETM13 (GST-
tag) 
BL21 (DE3) 22 
1CaM          16kDa 
pETM13 (no tag) 
BL21 (DE3) 23 
BL21 (DE3) Rosetta pLysS 24 
1EF-3/4         8kDa 
pETM13 (no tag) 
BL21 (DE3) 25 
BL21 (DE3) Rosetta pLysS 26 
2ABDa_SR1 
pETM20 
(His-tag + TrxA) 
57kDa 
2SR4_CaM 
pETM13 
(His-tag + DsbA) 
50kDa 
BL21 (DE3)  9 
BL21 (DE3) pLysS 10 
BL21 (DE3) Rosetta pLysS 11 
BL21 (DE3) Star 12 
2SR4_CaM 
pETM13 
(no tag) 
30kDa 
BL21 (DE3)  13 
BL21 (DE3) pLysS 14 
BL21 (DE3) Rosetta pLysS 15 
BL21 (DE3) Star 16 
2CaM          42kDa 
pETM13 (GST-
tag) 
BL21 (DE3) 27 
BL21 (DE3) Rosetta pLysS 28 
2EF-3/4       34kDa 
pETM13 (GST-
tag) 
BL21 (DE3) 29 
BL21 (DE3) Rosetta pLysS 30 
BL21 (DE3) Rosetta pLysS 31 
2EF-3/4         8kDa 
pETM13 (no tag) 
BL21 (DE3) 32 
BL21 (DE3) Rosetta pLysS 33 
1SR4_CaM 
pETM20 
(His-tag + TrxA) 
46kDa 
1ABDa_SR1 
pETM13 
(His-tag + DsbA) 
61kDa 
BL21 (DE3)  17 
BL21 (DE3) pLysS 18 
BL21 (DE3) Rosetta pLysS 19 
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4.3 Differential scanning fluorimetry (DSF) 
 DSF was carried out to find the optimal stable buffer for protein purification, in 
attempt to enhance the probability to obtain protein crystals. The initial protein buffer 
was 20 mM Tris-HCl pH 7.6, 150 mM NaCl and this was not the optimal buffer 
suggested by this technique for any of the tested proteins (Table 4.3). The melting 
curves for the constructs are shown in Figures 4.4 and 4.5. 
 
  
 
  
 
 
 
Figure 4.4 Melting curves of DSF 
experiments with the optimized buffer 
screen performed using an Mx3005 
Real-Time QPCR System (Stratagene). 
Y-axis corresponds to fluorescence 
signal in RFU. X-axis corresponds to 
temperature in Celsius (°C). A) 1AFL, 
B) 2AFL, C) 1hd, D) 2hd, E) 2Eh. 
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Figure 4.5 Melting curves of DSF with the optimized buffer screen. Y-axis corresponds to 
fluorescence signal in RFU. X-axis corresponds to temperature in Celsius (°C). A) 2ABDa performed 
using a Mastercycler eprealplex (Eppendorf), B) ∆2AFLY performed in an iQ5 multicolour Real-Time 
PCR Detection System (Bio-Rad). 
 
Table 4.3 Optimal stable buffers resulted from DSF and the difference (∆) in melting temperature (Tm) 
between initial and optimal buffers. 
 
Protein Optimal buffer ∆ Tm (°C) 
1AFL 20 mM TES pH 8.0, 150 mM NaCl 3 
2AFL 20 mM Na cacodylate pH 6.5, 150 mM NaCl 5 
∆2AFLY 20 mM HEPES pH 8.0, 150 mM NaCl 6 
1hd 20 mM Na cacodylate pH 6.5, 150 mM NaCl 4 
2hd 20 mM PIPES pH 7.5, 150 mM NaCl 4 
2ABDa 20 mM PIPES pH 7.5, 150 mM NaCl 8 
2Eh 20 mM Na cacodylate pH 6.5, 150 mM NaCl, 2 mM CaCl2 
2 
 
4.4 Purification of recombinant proteins 
4.4.1 Purification of AFL, 2Eh, hd and ABD 
Three steps of protein purification were carried out for AFL, 2AFLY and 2Eh 
(Figure 3.1) including gravity flow IMAC, ion exchange and size exclusion 
chromatography. In the case of hd, 2ABDa and 2ABDY (Figure 3.1) two-step 
purification protocol including gravity flow IMAC and size exclusion chromatography 
was sufficient to achieve high purity. 
Figures 4.6, 4.7, 4.8, 4.9 and 4.10 show the high levels of purity achieved after 
purification. In the case of AFL, hd or ABD purification, only the chromatograms of 
one construct [2AFL or 2AFL(Y); 2ABDa or 2ABDY)] or one isoform (1hd or 2hd) are 
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shown, since the constructs or isoforms present similar elution volume and purity. 
Purification yields are described in Table 4.4. 
Size exclusion chromatography for each protein was performed with the 
optimal buffer suggested by DSF (Table 4.3). 
 
 
 
 
 
 
 
Figure 4.6 Protein purification of 1AFL. A) 12% SDS-PAGE of fractions obtained from the gravity flow 
IMAC. Columns 1- cell lysate, 2- flow through, 3 - elution fraction. B) Ion exchange chromatography of 
1AFL carried out in a Resource Q column. C) SEC of 1AFL carried out in a Superdex200 HiLoad 
26/60 column equilibrated with 20 mM TES pH 8.0, 150 mM NaCl. D) 12% SDS-PAGE of 1AFL pooled 
fractions obtained from ion exchange chromatography and SEC. Columns: 1- pool fractions 
corresponding to the peak of ion exchange chromatography, highlighted in brown (B), 2- pool fractions 
corresponding to the peak of SEC, highlighted in yellow (D). 
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Figure 4.7 Protein purification of 2AFL (Figure 3.1). The pictures shown are for 2AFL to illustrate how 
the molecule behaves independent of the construct (2AFL or ∆2AFLY), with similar elution volumes 
and purity. A) Ion exchange chromatography of 2AFL carried out in a Resource Q column. B) SEC of 
2AFL carried out in a Superdex200 HiLoad 26/60 column equilibrated with buffers: 2AFL = 20 mM Na 
cacodylate pH 6.5, 150 mM NaCl; ∆2AFLY = 20 mM HEPES pH 8.0, 150 mM NaCl. C) 12% SDS-
PAGE of 2AFL pooled fractions obtained from gravity flow IMAC, ion exchange chromatography and 
SEC. Columns: 1- cell lysate, 2- pooled fractions obtained from gravity flow IMAC, 3- pooled fractions 
corresponding to the peak of ion exchange chromatography, highlighted in brown (A), 4- pooled 
fractions corresponding to the peak of SEC, highlighted in yellow (B). 
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Figure 4.8 Protein purification of 2Eh (Figure 3.1). A) Ion exchange chromatography of 2Eh carried 
out in a Resource Q column. B) SEC of 2Eh carried out in a Superdex200 HiLoad 26/60 equilibrated 
with 20 mM Na cacodylate pH 6.5, 150 mM NaCl, 2 mM CaCl2. C) 12% SDS-PAGE of 2Eh of pooled 
fractions obtained from gravity flow IMAC, ion exchange chromatography and SEC. Columns: 1- cell 
lysate, 2- flow through, 3- washing step, 4- pooled fractions obtained from gravity flow IMAC, 5- pooled 
fractions corresponding to the peak of ion exchange chromatography, highlighted in brown (A), 6- 
pooled fractions corresponding to the peak of SEC, highlighted in yellow (B). 
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Figure 4.9 Protein purification of hd (Figure 3.1). The pictures shown are for 2hd to illustrate how the 
hd molecule behaves independent of the isoform (1hd or 2hd), since they present similar elution 
volume and purity. A) 12% SDS-PAGE of 2hd pooled fractions obtained from the gravity flow IMAC. 
Columns 1- cell lysate, 2- flow through and 3- elution fraction. B) SEC of 2hd carried out in a 
Superdex200 HiLoad 26/60 column equilibrated with buffers: 1hd = 20 mM Na cacodylate pH 6.5, 150 
mM NaCl; 2hd = 20 mM PIPES pH 7.5, 150 mM NaCl. C) 12% SDS-PAGE of pooled fractions 
obtained from SEC. Columns: 1- pooled fractions corresponding to the peak of 2hd SEC, highlighted 
in yellow (B), 2- pooled fractions obtained from SEC of 1hd (chromatogram not shown). 
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Figure 4.10 Protein purification of 2ABD. A) 15% SDS-PAGE of 2ABDY pooled fractions obtained 
from the gravity flow IMAC. Columns 1- cell lysate, 2- flow through and 3- elution fraction. B) SEC of 
2ABDY just to show how the ABD molecule behaves, independent of the construct (2ABDa or 2ABDY; 
Figure 3.1). This chromatography was carried out in a Superdex75 HiLoad 26/60 column equilibrated 
with 20 mM PIPES pH 7.5, 150 mM NaCl, for both constructs. C) 15% SDS-PAGE of pooled fractions 
obtained from SEC. Columns 1- pooled fractions corresponding to the peak of 2ABDY size exclusion 
chromatography, highlighted in yellow (B), 2- SEC elution of 2ABDa (chromatogram not shown). 
 
Table 4.4 Protein yield per litre of culture. 
 
Protein Yield/l (mg) 
1AFL 6 
2AFL (Y) 4 
2ABDa 12 
2ABDY 20 
1hd 6 
2hd 4 
2Eh 3 
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4.4.2 Purification of a co-expression system: 2ABDa_SR1 + 2SR4_CaM 
 The most promising complex obtained from co-transformation experiments 
[Sample 15 in Figure 4.3: 2ABDa_SR1 (His-tagged) + 2SR4_CaM (not tagged)] was 
induced over night at 20°C. After this period the supernatant of the cell lysate was 
submitted to gravity flow IMAC and size exclusion chromatography. The low purity 
and low concentration of the eluted complex were assessed by SDS-PAGE (Figure 
4.11). 
 
 
Figure 4.11 Purification of the 2ABDa_SR1 + 2SR4_CaM complex. A) 15% SDS-PAGE of pooled 
fractions obtained from the gravity flow IMAC. Columns 1- cell lysate, 2- flow through, 3- elution 
fraction and 4- insoluble portion of the cell lysate (pellet). B) SEC carried out in a Superdex200 HiLoad 
26/60 column equilibrated with 20mM Tris-HCl pH 7.6, 150mM NaCl. C) 15% SDS-PAGE of fractions 
obtained from SEC. All columns correspond to the peak highlighted in yellow (B). D) 15% SDS-PAGE 
of fractions obtained from SEC. Columns 1, 2 and 3- fractions of the peak highlighted in pink (B); 4, 5, 
6, 7, and 8- fractions of the peak highlighted in purple (B). 
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4.4.3 Co-purification experiments 
4.4.3.1 α-actinin 
 A second approach used to try to obtain a complex of different α-actinin 
domains was co-purification of the desired components of the complex. Cells of 
individual components (ABD_SR1; EF-3/4; CaM) were broken together after protein 
induction and the supernatant of the cell lysate was submitted to gravity flow IMAC. 
In Figure 4.12 it is possible to see that co-purification experiments did not result in 
correct complex formation due to degradation, insolubility and/or shortage in 
production of one of the components. 
 
 
 
 
 
 
 
Figure 4.12 15% SDS-PAGE of fractions obtained from the co-purification experiments by gravity flow 
IMAC co-purification. A) 1ABDa_SR1 (His-tag + TrxA) + 1EF-3/4 (not tagged). Columns: 1- cell lysate, 
2- flow through, 3- wash, 4, 5, 6, 7- elution fractions and 8- insoluble fraction of the cell lysate (pellet). 
B) 2ABDa_SR1 (His-tag + TrxA) + 2EF-3/4 (GST-tag). Columns: 1- cell lysate, 2- flow through, 3- 
wash, 4, 5, 6, 7- elution fractions and 8- insoluble fraction of the cell lysate (pellet). C) 1ABDa_SR1 
(His-tag + TrxA) + 1CaM (GST-tag). Columns: 1- cell lysate, 2- flow through, 3- wash, 4- elution 
fractions and 5- insoluble fraction of the cell lysate (pellet). D) 2ABDa_SR1 (His-tag + TrxA) + 2CaM 
(not tagged). Columns: 1- cell lysate, 2- flow through, 3- wash, 4, 5, 6, 7, 8- elution fractions and 9- 
insoluble fraction of the cell lysate (pellet). 
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4.4.3.2 hd + PDZ domain of ZASP 
 To understand α-actinin regulation, experiments to form a complex between 
2hd and PDZ in the presence and absence of the phospholipid LPA were carried out. 
The initial trial was performed by preparative size exclusion chromatography in the 
absence of LPA as a pilot experiment, resulting in a complex between PDZ (GST-
tagged) and the excess of 6x His – SR3_SR4_CaM (Figure 4.13). 
Analytical size exclusion chromatography was, subsequently, performed with 
non-tagged PDZ and 2hd without any excess of 6x His – SR3_SR4_CaM, in the 
absence and presence of different ratios of LPA. This analytical study was performed 
to verify whether the LPA would enhance complex formation (Figure 4.14). 
Experiments preformed at molar ratios 1:1:3 and 1:1:5 of 2hd, PDZ and LPA show 
that no complex formation was detected under the condition used (20 mM Tris-HCl 
pH 7.6, 150 mM NaCl). 
 
 
 
 
Figure 4.13 Formation of 2hd (his-tagged) and PDZ (GST-tagged) complex. A) Preparative SEC 
carried out in a Superdex200 HiLoad 26/60 column equilibrated with 20 mM Tris-HCl pH 7.6, 150 mM 
NaCl. B) 12% SDS-PAGE of fractions obtained from SEC. Columns: 1, 2, 3, 4, 5, 6 and 7- elution 
correspondent to the peak highlighted in gray (A); 8, 9, 10 and 11- elution correspondent to the peak 
highlighted in green (A, hd); 12, 13, 14 and 15- elution correspondent to peak highlighted in red (A, 
formation of PDZ (GST) and the excess of 6x His – SR3_SR4_CaM complex). 
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Figure 4.14 Analytical SEC of 2hd + PDZ (not tagged), carried out in a Superdex200 10/300 GL 
column equilibrated with 20 mM Tris-HCl pH 7.6, 150 mM NaCl. A) 2hd (peak highlighted in green). B) 
PDZ (peak highlighted in blue). C) a molar ratio 1:1 of 2hd and PDZ. D) a molar ratio 1:1:3 of 2hd, 
PDZ and LPA (formation of a new peak highlighted in orange). E) a molar ratio 1:1:5 of 2hd, PDZ and 
LPA. F) 15% SDS-PAGE of pooled fractions obtained from the analytical SEC of a molar ratio 1:1:3 
experiment with the three components (D). Columns 1- 2hd (control); 2- PDZ (control); 3- elution 
correspondent to peak highlighted in orange; 4- elution correspondent to peak highlighted in green 
(hd), 5- elution correspondent to peak highlighted in blue (PDZ). 
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4.5 Dynamic light scattering (DLS) 
 DLS was used as a protein quality control before crystallization trials. All 
studied proteins presented low level of polydispersity (%Pd; Table 4.5). 
 
Table 4.5 DLS measured in a DynaPro (Protein Solutions Inc.) at 22° C with 100 acquisitions at 1 s 
interval each. The table lists radius, %Pd and concentration data for each protein. 
 
SAMPLE R (nm) %Pd 
CONCENTRATION 
(mg/ml) 
2ABDY 2.1 15.6 10.0 
1AFL - EDTA 7.7 13.9 4.0 
1AFL - CaCl2 8.1 13.5 5.0 
6x His - ∆2AFLY 7.5 14.1 4.7 
∆2AFLY 7.8 15.1 4.7 
1hd 5.4 13.1 10.0 
2hd 5.5 13.4 4.0 
2Eh 6.2 11.5 6.0 
 
4.6 Crystallization trials and protein reductive methylation 
 After purification, all 6x His-tagged proteins (AFL, 2Eh, hd and ABD) were 
submitted to crystallization trials with methods and conditions described in the 
“materials and methods” section (Chapter 3).  
 Since no crystal hits were obtained, protein reductive methylation experiments 
was carried out, expecting that changes in the surface charges would enhance 
crystal formation. This resulted in crystal hits of Eh2 (6x His – 2Eh Met-K) and 2AFL 
(6x His – 2AFL Met-K). 
Initial crystal hits of 6x His – 2Eh Met-K were obtained with protein 
concentration around 6.5 mg/ml and mother liquor conditions: A) 0.1 M Bis-tris 
propane pH 6.5, 0.2 M Na/K phosphate, 20% PEG 3350; B) 0.1 M Bis-tris pH 5.5, 0.2 
M ammonium acetate, 25% PEG 3350; C) 0.1 M Bis-tris pH 6.5, 0.2 M ammonium 
acetate, 25% PEG 3350; D) 0.1 M Bis-tris pH 5.5, 0.2 M NaCl, 25% PEG 3350; E) 
0.1 M Bis-tris pH 5.5, 0.2 M MgCl2, 25% PEG 3350; F) 0.1 M Tris-HCl pH 8.5, 0.2 M 
MgCl2, 25% PEG 3350 (Figure 4.15). These hits were obtained at 22° C and sitting 
drop vapour diffusion method. Optimization of crystallization conditions is in progress. 
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Figure 4.15 Crystal hits of 6x His - 2Eh Met-K. Protein concentration used was ~6.5 mg/ml in 20 mM 
Na cacodylate pH 6.5, 150 mM NaCl. Hits obtained after initial screen: A) 0.1 M Bis-tris propane pH 
6.5, 0.2 M Na/K phosphate, 20% PEG 3350; B) 0.1 M Bis-tris pH 5.5, 0.2 M ammonium acetate, 25% 
PEG 3350; C) 0.1 M Bis-tris pH 6.5, 0.2 M ammonium acetate, 25% PEG 3350; D) 0.1 M Bis-tris pH 
5.5, 0.2 M NaCl, 25% PEG 3350; E) 0.1 M Bis-tris pH 5.5, 0.2 M MgCl2, 25% PEG 3350; F) 0.1 M Tris-
HCl pH 8.5, 0.2 M MgCl2, 25% PEG 3350. 
 
The crystal hits of 6x His – 2AFL Met-K were obtained with protein 
concentration around 4.7 mg/ml. Initial hits were obtained in mother liquor conditions: 
A) 0.1 M Na thiocyanate, 20% PEG 3350; B) 0.1 M Bis-tris pH 5.5, 0.1 M ammonium 
acetate, 17% PEG 10000; C) 0.1 M MES pH 6.0, 10% PEG 6000. Optimization 
yielded improved crystal quality at 14° C in mother liquor conditions: D) 0.1 M Tris-
HCl pH 7.4, 0.2 M Na thiocyanate, 20% PEG smear; E) 0.2M Na thiocyanate, 20% 
PEG smear; F) 0.2 M Na thiocyanate, 17% PEG 10000 (Figure 4.16) and hanging 
drop vapour diffusion method. 
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Figure 4.16 Crystal hits and further optimization hits of 6x His - 2AFL Met-K. Protein concentration 
was ~4.7 mg/ml in 20 mM Na cacodylate pH 6.5, 150 mM NaCl. Hits obtained after initial screen: A) 
0.1 M Na thiocyanate, 20% PEG 3350; B) 0.1 M Bis-tris pH 5.5, 0.1 M ammonium acetate, 17% PEG 
10000; C) 0.1 M MES pH 6.0, 10% PEG 6000. Hits obtained after optimization: D) 0.1 M Tris-HCl pH 
7.4, 0.2 M Na thiocyanate, 20% PEG smear; E) 0.2 M Na thiocyanate, 20% PEG smear; F) 0.2 M Na 
thiocyanate, 17% PEG 10000. 
 
4.7 Crystallization trials and protein surface entropy reduction (SER) 
 SER was used in an attempt to grow better crystals of 6x His – 2AFL. 
The clusters for residue mutation suggested by the web site 
http://nihserver.mbi.ucla.edu/SER/ were E23A/E24A/E25A, E149A/E150A, 
E260A/Q261A/E263A and E310A/K311A. Positive results were obtained with the 
triple-site mutant 6x His – ∆2AFL E23A/E24A/E25A and the double-site mutant 6x 
His – ∆2AFL E310A/K311A. These mutants were submitted to three-step protein 
purification and subsequent crystallization trials 
Despite the attained high purity, the triple-site mutant presented a very low 
expression level. This proved insufficient for crystallization trials, as checked by PCT. 
On the other hand, the concentration obtained for the double-site mutant was enough 
to set up crystallization plates. Crystalline like structures were obtained in mother 
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liquor conditions: A) 0.1 M Tris-HCl pH 8.5, 0.2 M NaCl, 25% PEG 3350; B) 0.1 M 
Tris-HCl pH 8.5, 0.8 M K/Na tartrate, 0.5% PEG MME 5000 (Figure 4.17). 
 
 
 
Figure 4.17 Initial crystalline hits of the double-site mutant 6x His - ∆2AFL E310A/K311A. The protein 
concentration was ~4.7 mg/ml in 20mM Na cacodylate pH 6.5, 150 mM NaCl. Hits obtained after initial 
screen: A) 0.1 M Tris-HCl pH 8.5, 0.2 M NaCl, 25% PEG 3350; B) 0.1 M Tris-HCl pH 8.5, 0.8 M K/Na 
tartrate, 0.5% PEG MME 5000. 
 
Since the optimization of initial crystal hits was unsuccessful, the 6x His – 
∆2AFL E310A/K311A was submitted to protein reductive methylation (6x His – 
∆2AFL Met-K). Needles about 100 – 120 µm long and 10 – 20 µm wide grew after 
optimization screens at 14° C in protein concentration around 4.7 mg/ml. The initial 
condition was 0.1 M Mg formate, 15% PEG 3350 and the best crystals were obtained 
by hanging drop diffusion method in mother liquor 0.2 M Na formate, 6% PEG smear 
(Figure 4.18). 
 
 
 
Figure 4.18 Crystal hits of 6x His - ∆2AFL Met-K. The protein concentration was ~4.7 mg/ml in 20 mM 
Na cacodylate pH 6.5, 150 mM NaCl. A) Initial condition: 0.1 M Mg formate, 15% PEG 3350; B) 
Optimized condition: 0.2 M Na formate, 6% PEG smear. 
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4.7.1 Cleavage of the flexible N-terminal of ∆2AFL E310A/K311A (∆2AFLY) 
 In order to decrease the flexibility of the α-actinin full length (AFL) and grow 
better crystals, a construct for 2AFL WT and mutants excluding the first eighteen 
amino acids was designed. DNA amplification (section 4.1.1), protein expression and 
purification (items 4.2.1 and 4.4.1) were shown previously. Positive results were 
obtained for the mutant ∆2AFL E310A/K311A and after protein reductive methylation 
(6x His – ∆2AFLY Met-K), tiny needles grew at 14° C (protein concentration around 
4.7 mg/ml). The initial condition was the same as for the 6x His – ∆2AFL Met-K (0.1 
M Mg formate, 15% PEG 3350) but the best crystal hits were obtained in hanging 
drops in mother liquor 0.2 M Mg formate, 6% PEG smear, with and without 0.01 mM 
EDTA as additive (Figure 4.19). 
 
 
 
Figure 4.19 Crystal hits of 6x His - ∆2AFLY Met-K. The protein concentration was ~4.7 mg/ml in 20 
mM HEPES pH 8.0, 150 mM NaCl. Hit obtained after initial condition: A) 0.1 M Mg formate, 15% PEG 
3350. Hits obtained after optimization: B) 0.2 M Mg formate, 6% PEG smear; C) 0.2 M Mg formate, 
5% PEG smear, 0.01 M EDTA (as additive). 
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4.7.2 6x His - tag cleavage 
 Another strategy to grow better ∆2AFLY crystals involved the 6x His tag 
cleavage. The ∆2AFLY expression, purification, protein reductive methylation 
(∆2AFLY Met-K) and crystallization trials followed the same procedure established 
for 6x His – ∆2AFLY Met-K. This resulted in crystals that were 250 – 300 µm long 
and 30 – 35 µm wide. Some of these crystals grew in different crystal forms when 
compared to 6x His – ∆2AFLY Met-K. The initial condition was the same as for the 6x 
His – ∆2AFL Met-K (0.1 M Mg formate, 15% PEG 3350) but the best crystals grew in 
0.2 M Mg formate, 5% PEG smear and 0.01 mM EDTA as additive (Figure 4.20). 
 
 
 
Figure 4.20 Crystal hits of ∆2AFLY Met-K. The protein concentration was ~4.7 mg/ml in 20 mM 
HEPES pH 8.0, 150 mM NaCl. The crystals were obtained under the condition: 0.2 M Mg formate, 5% 
PEG smear, 0.01 M EDTA (as additive). 
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4.8 Preliminary data collection of AFL E310A/K311A 
 X-ray data for α-actinin AFL were collected on ID23-1 and ID23-2 ESRF 
beamlines, presenting a nice evolution of resolution according to the constructs. The 
6x His - ∆2AFL Met-K crystals were very small and diffracted to around 11 Å (Figure 
4.21A) on beamline ID23-1. On the other hand, crystals of the truncated version of 
full length (6x His - ∆2AFLY Met-K) yielded partial data-set to about 4 Å on the micro 
focus beamline ID23-2 (Figure 4.21B). Three data set were merged in the attempt to 
obtain one complete data; nevertheless, this approach was unsuccessful (Table 4.6). 
The ∆2AFLY Met-K crystals were of bigger size and generated data set to 
about around 4 Å on the beamline ID23-1 (Figure 4.21C). Data processing statistics 
are listed in Table 4.7. 
 
Table 4.6 Merged scaling statistic of 6x His – ∆2AFLY Met-K data sets. Values in brackets refer to the 
highest resolution shell. 
 
Beamline ID23-2 
Wave length (Å) 0.87 
Space group P222 
Unit cell parameters a = 73.3 Å, b = 102.6 Å, c = 181.7 Å 
α = β = γ = 90° 
Unique reflections 8601 (380) 
Resolution (Å) 4.5 
Completeness (%) 79.6 (61.6) 
R-meas (%) 26.4 (68.4) 
 
 
Table 4.7 Data collection and processing statistics of ∆2AFLY Met-K. Values in brackets refer to the 
highest resolution shell. 
 
Beamline ID23-1 
Wave length (Å) 0.97 
Space group P222 
Unit cell parameters a = 72.4 Å, b = 101.4 Å, c = 179.8 Å 
α = β = γ = 90° 
Unique reflections 4352 (288) 
Resolution (Å) 6.7 
Completeness (%) 94.6 (87.8) 
R-meas (%) 9.6 (40.3) 
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Figure 4.21 Diffraction patterns of ∆2AFL and ∆2AFLY E310A/K311A Met-K collected at 100 K and 
displayed by ADXV software. A) 6x His - ∆2AFL Met-K collected on ESRF beamline ID23-1 to a 
resolution ~11 Å, B) 6x His - ∆2AFLY Met-K collected on ESRF micro focus beamline ID23-2 to a 
resolution ~4 Å and C) ∆2AFLY Met-K collected on ESRF beamline ID23-1 to a resolution ~4 Å. 
 
4.9 Actin binding domain (ABD): WT versus mutant 
 The single-site mutants (∆2ABDa) designed for α-actinin isoform 2 to validate 
the proposed PIP2 binding site within the ABD (Franzot et al., 2005) were R163E, 
R169E and R192E. Positive results were obtained for ∆2ABDa R169E and ∆2ABDa 
R192E mutants. Expression and purification followed the protocol established for the 
ABDa WT (purification of WT is shown at Figure 4.10). 
 The major difference between the three samples was in the protein expression 
and purification yields. The mutant ∆2ABDa R169E (yield per litre = 8 mg) is 
expressed in lower level than the WT (yield per litre = 12 mg) and the mutant 
∆2ABDa R192E (yield per litre = 18 mg). However, the expression of the mutant 
∆2ABDa R192E yielded increased amount of protein than the WT. 
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 Binding of α-actinin 2ABDa WT and its mutants to different types of 
phosphoinositides was studied using different strategies. The first approach 
employed the PiP strips binding method, using as a negative control the protein 
chlorite dismutase (kindly provided by Julius Kostan). No significant binding was 
observed under the conditions used (Figure 4.22; N-terminal his-tagged proteins in 
20 mM Tris-HCl pH 7.6 and 100 mM NaCl). 
 
 
 
Figure 4.22 PiP strips binding assays for 2ABDa WT and the mutants ∆2ABDa R169E, ∆2ABDa 
R192E. A) 2ABDa WT, B) ∆2ABDa R169E, C) ∆2ABDa R192E, D) chlorite dismutase and E) 
illustration of a PiP strip showing the contents [phosphatidylinositol (PtdIns), phosphatidylinositol 3-
phosphate (PtdIns(3)P), phosphatidylinositol 4-phosphate (PtdIns(4)P), phosphatidylinositol 5-
phosphate (PtdIns(5)P), phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2), phosphatidylinositol 
4,5-biphosphate (PtdIns(4,5)P2), phosphatidylinositol 3,4-biphosphate (PtdIns(3,4)P2), 
phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3)]and their concentrations. 
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4.9.1 Differential scanning fluorimetry (DSF) 
 DSF was used to study the binding of IP6 to 2ABDa WT. Increasing IP6 
concentrations were used in an attempted to relate IP6 concentration and protein 
stability. Figure 4.23 shows a loss of protein stability at IP6 concentration of around 
0.6 mM, which corresponds to a tenfold IP6 excess. 
 
 
 
Figure 4.23 Stability of 2ABDa WT versus IP6 concentration. Y-axis corresponds to melting 
temperature in Celsius (°C) and X-axis corresponds to IP6 concentration. 
 
4.9.2 Circular dichroism (CD) 
 CD was performed at near-UV in order to follow the binding of 2ABDa WT and 
IP6. The protein to IP6 concentration ratio was 1:10 and the CD spectra show no 
tertiary conformational changes (Figure 4.24). 
 
 
 
Figure 4.24 Near-UV CD spectra of 2ABDa WT and IP6 at protein:IP6 ratio 1:10. Y-axis corresponds 
to CD data (mdegCD) and X-axis corresponds to wave length (nm). 
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4.9.3 Nuclear magnetic resonance spectroscopy (NMR) 
 2D-NMR was performed to study the binding of 2ABDa WT and IP3. The 
spectrum shows small shifts in the signal of 15N-2ABDa WT (Figure 4.25). Validation 
of these shifts was done through a selective T1 measurement with non-labelled 
2ABDa WT and IP3. No difference in the relaxation time (T1) was observed. 
 
 
 
Figure 4.25 Part of the superposition HSQC spectra showing small shifts in the 15N-2ABDa WT signal 
by increasing IP3 concentration. Blue: 1mM 15N-2ABDa WT, green: protein and IP3 molar ratio 1:1 
between protein and IP3, yellow: 1:2 molar ratio, red: 1:4 molar ratio and cyan: 1:6 molar ratio. 
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4.9.4 Isothermal titration calorimetry data (ITC) 
 ITC was applied to assess the binding of 2ABDa and IP3. 2ABDa WT and its 
mutants ∆2ABDa R169E, ∆2ABDa R192E were titrated with IP3 and the results are 
presented in Figure 4.26. Dissociation constants (Kd) were high: 1.8mM for 2ABDa 
WT, 1.2mM for ∆2ABDa R169E and 2.8mM for ∆2ABDa R192E (Table 4.8). 
 
 
 
Figure 4.26 ITC data acquired at 25°C by titrating IP3 to 2ABDa WT and mutants. Representative raw 
ITC data (top) and integrated data fits (bottom) are shown for: A) 2ABDa WT, B) ∆2ABDa R169E and 
C) ∆2ABDa R192E. 
 
Table 4.8 Isothermal titration analysis of 2ABDa WT and mutants. 
 
Sample ∆H (cal/mol) 
∆S 
(cal/mol/K) 
-T∆S 
(cal/mol) 
∆G 
(cal/mol) Ka (M
-1) Kd (mM) 
2ABDa 
WT - 61.2 ± 0.3 - 193 57.9 - 3.3 568 ± 36 1.8 ± 0.1 
∆2ABDa 
R169E - 54.2 ± 0.9 - 169 50.7 - 3.5 813 ± 19 1.2 ± 0.03 
∆2ABDa 
R192E - 104 ± 0.5 - 337 101.1 -2.9 358 ± 20 2.8 ± 0.1 
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4.9.5 Protein crystallization: ABDa versus ABDY 
 With the aim to solve the structure of ABD in complex with IP3 or IP6, 2ABDa 
was submitted to crystallization trials. Since no crystals were obtained, an attempt 
was made to cleave the N-terminal 6x His-tag. This proved unsuccessful and a new 
construct based on the known structure of the human α-actinin ABD isoform 3 
structure (Franzot et al., 2005) was designed. The first eighteen flexible residues 
(2ABDY) were excluded from the new construct and cloning, protein expression and 
purification followed the protocol established for 2ABDa (items 4.2.1 and 4.4.1). 
 After cleavage of the N-terminal 6x His-tag, crystal hits were obtained in 
different conditions (Figure 4.27) with a protein concentration around 10 mg/ml. 
After optimization of selected hits, the crystals were soaked in cryo-solutions 
containing IP3 or IP6 in different concentrations prior to cryo-cooling in liquid 
nitrogen. 
 
 
Figure 4.27 Crystal hits of 2ABDY used for soaking in IP3 or IP6. Protein concentration was ~10 
mg/ml in 20 mM PIPES pH 7.5, 150 mM NaCl. Hits obtained after initial screening: A) 0.1 M MMT pH 
6.0, 25% PEG 1500 in sitting drops, vapour diffusion method; B) 0.1 M MMT pH 5.0, 25% PEG 1500 
and sitting drop vapour diffusion method. Hits obtained after optimization in hanging drops, vapour 
diffusion method: C) 0.1 M MMT pH 6.0, 25% PEG MME 2000; D) 0.1 M MMT pH 6.0, 25% PEG 
1500; E) 0.1 M MMT pH 5.0, 25% PEG 3350 and F) 0.1 M Na acetate pH 5.6, 0.2 M ammonium 
acetate, 25% PEG 3350 + PEG 1500. 
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 Some co-crystallization trials with IP3 were also performed, producing crystal 
hits in different conditions (Figure 4.28). 
 
 
 
Figure 4.28 Crystals of 2ABDY + IP3. Protein concentration was ~10 mg/ml in 20 mM PIPES pH 7.5, 
150 mM NaCl. The protein to IP3 molar ratio was 1:10. Hits obtained after initial screening: A) 0.1 M 
Bis-Tris pH 5.5, 25% PEG 3350; B) 0.1 M Bis-Tris pH 5.5, 0.2 M ammonium acetate, 25% PEG 3350. 
Hit obtained after optimization: C) 0.1 M Na acetate pH 5.5, 0.2 M ammonium acetate, 25% PEG 3350 
+ PEG 1500. 
 
4.9.6 Data collection, processing and structure determination 
 Eight data sets for 2ABDY crystals soaked in or co-crystallized with IP3 or IP6 
under different conditions were collected on beamline ESRF ID23-1. The crystals 
diffracted strongly and full data sets to a resolution around 1.8 Å were collected. 
Figure 4.29 shows the diffraction pattern of a 2ABDY crystal soaked in 12mM IP3. 
The structure was solved by molecular replacement, using as search model 
the structure of α-actinin ABD isoform 3 [PDB entry 1WKU; (Franzot et al., 2005)]. All 
structures determined presented similar statistics and Table 4.9 shows a 
representative data collection, processing and refinement statistics. No IP3 or IP6 
binding to the protein was detected in the difference electron density maps. The final 
structure of 2ABDY refined at 1.8 Å resolution is shown in Figure 4.30, after 
validation through MolProbity (Davis et al., 2004). Residues involved in the CH 
domains interactions (W136 and R243) are highlighted in the structure by sticks. 
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Figure 4.29 Diffraction pattern of 2ABDY collected at 100 K and displayed by ADXV software. This 
data set was collected from a 2ABDY crystal soaked in 12 mM IP3 on beamline ID23-1 to a resolution 
of 1.8Å. 
 
 
Table 4.9 Data collection processing of 2ABDY: (A) and refinement (B) statistics. 
 
A) Data collection  
Beamline ID23-1 
Wave length (Å) 1.07 
Space group P1 
Unit cell parameters a = 38.4 Å, b = 46.4 Å, c = 70.2 Å 
α = 73°, β = 80°, γ = 75° 
Unique reflections 38623 (5672) 
Resolution (Å) 1.8 
Completeness (%) 93.1 (84.4) 
R-meas (%) 6.9 (39.5) 
B) Refinement  
No. Reflections 37719  
Resolution (Å) 1.8 
Rfactor (%) 0.204 
Rfree (%) 0.237 
No. protein atoms 7269 
No. water molecules 476 
r.m.s.d. Bond lengths (Å) 0.009 
r.m.s.d. Bond angles (deg.) 1.119 
Overall B-value (Å2) 19.04 
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Figure 4.30 Overall structure of 2ABDY refined at 1.8 Å. The domain CH1 is coloured in blue, the CH2 
is coloured in red and the α-helix are indicated by letters. The structure presents close conformation 
and the residues involved in the CH domains interactions are highlighted in sticks: W136 and R243. 
The picture was made using the program PyMOL (DeLano Scientific LLC), after validation through 
MolProbity (Davis et al., 2004). 
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4.10 Small angle X-ray scattering (SAXS): 2Eh, AFL and hd 
 The interaction of N-terminal and C-terminal ends of the α-actinin antiparallel 
dimer molecule was analyzed using SAXS. Data for human α-actinin both isoforms 
AFL, hd in different conditions (± Ca2+ for isoform 1) and for E. histolytica α-actinin 
(2Eh) were collected on the X33 beamline (DESY, Hamburg). 
 Analysis of SAXS data presented maximum intramolecular distance for 2Eh ~ 
240 Å, for 2hd ~ 190 Å and for 2AFL ~ 350 Å (Figure 4.31, inset). Additionally for 
2AFL the distance distribution function presented a skewed appearance typical for 
elongated molecules. The low resolution molecular envelopes generated by SAXS 
data had expected sizes and shapes for all α-actinin constructs: 2Eh presented ~250 
Å, 2hd ~194 Å and 2AFL ~ 365 Å, when compared to crystal structures of individual 
domains (central rod domain ~ 240 Å, ABD ~ 60 Å and EF-3/4 ~ 15 Å lengths). 
 Experimental X-ray scattering pattern for 2Eh, 2hd and 2AFL are shown in 
Figures 4.31. χ-values for fitting of ab initio models to experimental data are shown in 
Table 4.10. 
 
 
Figure 4.31 SAXS experimental X-ray scattering pattern for 2AFL (1), 2hd (2) and 2Eh (3) Full lines 
represent the scattering computed from a typical ab initio model. Distance distribution functions are 
displayed in the inset: 1- 2AFL, 2- 2hd and 3- 2Eh. 
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Table 4.10 SAXS χ-values for fitting of ab initio models to experimental data. 
 
Sample χ-value 
1AFL 1.65 
1hd 1.36 
2AFL 1.86 
2hd 1.24 
2Eh 2.4 
 
The molecular envelope of 2Eh, 2hd and 2AFL were fit with the structure of the 
individual domains by rigid body modelling. Models together with molecular 
envelopes are shown in Figure 4.32. χ-values for fitting of rigid body modelling to 
experimental data are shown in Table 4.11. 
 
Table 4.11 SAXS χ-values for fitting of rigid body modelling to experimental data rigid body modelling 
χ-values. 
 
Sample χ-value 
2AFL 2.40 
2hd 1.65 
2Eh 2.60 
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Figure 4.32 SAXS rigid body models for 2AFL (1), 2hd (2) and 2Eh (3) calculated using the program 
BUNCH (Petoukhov and Svergun, 2005). Molecular envelopes are represented with grey mesh and 
missing residues modelled as dummy atoms are represented as blue links. 
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5. DISCUSSION AND PERSPECTIVES 
 
5.1 Cloning of α-actinin domains 
 The pETM system plasmids have the NcoI recognition site (5’ C▼CATGG 3’) 
immediately after the TEV cleavage site. This is the best approach for further 
structural studies since it involves addition of only one residue to the protein 
sequence. Given that α-actinin DNA has several NcoI recognition sites within its 
sequence, a strategy that would allow cloning these fragments into the pETM 
plasmids was necessary. 
 It involved the design of the forward oligonucleotides with a BsaI recognition 
site (5’ GGTCTC(N)1▼ 3’) since it creates compatible ends to NcoI (Figure 5.1). This 
approach resulted, after TEV cleavage, in the addition of one glycine or alanine at the 
N-terminus (before the first residue of the protein). 
 
 
 
Figure 5.1 Schematic view of BsaI (green) and NcoI (red) compatible ends for cloning of human α-
actinin inserts (yellow) into pETM expression plasmids (blue). 
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5.2 Actin binding domain (2ABD) 
Series of binding studies were performed to validate the putative PiP2 binding 
site within the ABD (Franzot et al., 2005). Three single-site mutants (∆2ABDa R163E, 
∆2ABDa R169E and ∆2ABDa R192E) were designed with this purpose (Figure 5.2). 
Arginine (R) residues were mutated to glutamate (E) to validate the predicted PiP2 
binding residues since the repulsion between the negatively charged residue E and 
the PiP2 head group (inositols) would hinder PiP2 and ABD interaction. 
 The ABD of α-actinin isoform 2 construct (2ABDa WT) was designed starting 
at residue A35 (number corresponding to α-actinin isoform 2) exactly at the beginning 
of the actin-binding domain (Figure 3.1), according to the crystallographic structure of 
ABD isoform 3 (Franzot et al., 2005). Two out of three single-site mutants were 
successfully cloned, expressed and purified to homogeneity: ∆2ABDa R169E and 
∆2ABDa R192E. 
 
 
Figure 5.2 Putative PiP2 binding residues of 2ABD, residues involved are highlighted in sticks. The 
positive single-site mutants used on this work were ∆2ABDa R169E and ∆2ABDa R192E. 
____________________________________________DISCUSSION AND PERSPECTIVES 
74 
 
 The initial binding study consisted of assays to assess the ability of the 2ABDa 
WT and mutants to bind different phosphoinositides. The experiments were carried 
out using PiP strips and no binding was observed with any of the ABD samples 
(Figure 4.22A - C). On the other hand, the chlorite dismutase from Nitrospira used as 
negative control showed binding to several phosphoinositides, including PiP2 (Figure 
4.22D). Given that the control experiment was not reliable, these results were not 
taken in further consideration and alternative approaches were consequently 
employed to characterize the WT and the mutants. 
 Subsequent experiments involved use of inositols IP3 or IP6 as a substitute of 
PiP2 to avoid the interference of the hydrophobic tail in the binding studies or in 
further crystallization trails of the complex. IP3 is the soluble head group of PiP2, with 
three phosphates, while IP6 has six phosphates. 
 In an attempt to relate phosphoinositides influence on 2ABDa WT stability, we 
employed differential scanning fluorimetry (DSF). Results showed 2ABDa WT is 
stable with increasing IP6 concentration up to tenfold molar excess, when the melting 
temperature decreases (Figure 4.23), indicating protein destabilization. This could be 
caused by either by IP6 binding or most probably by protein aggregation upon 
increased amount of IP6, which could generate changes in pH and ionic strength of 
the sample. 
 Near-UV CD experiments were carried out to monitor potential protein tertiary 
conformational changes upon binding of IP6. 2ABDa WT to IP6 molar ratio was 1:10 
to guarantee binding and no notable changes in tertiary structure were detected 
(Figure 4.24). This is in line with observations on other phosphoinositides binding 
domain, PH domain, which also do not undergo considerable structural changes 
upon ligand binding (Baraldi et al., 1999; Thomas et al., 2002). 
 Since IP6 carrying six phosphate groups might not be the highest affinity 
binder of α-actinin ABD, IP3 was used as ligand in all subsequent experiments. 
 2D-NMR experiments were carried out using the 15N-labeled 2ABDa WT at 
different IP3 concentrations. Very small protein signal shifts were observed (Figure 
4.25), preventing the determination of Kd from this titration experiment. Thus, a 
selective T1 measurement on the ligand IP3 was designed to validate the small 
protein shifts. No differences in the relaxation time (T1) of the ligand were observed, 
indicating inexistent or very weak binding under experimental conditions. 
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 Quantitative characterization of 2ABDa WT and mutants binding to IP3 was 
performed through ITC. Data were acquired titrating IP3 to mutants ∆2ABDa R169E, 
∆2ABDa R192E and to wild type 2ABDa WT (Figure 4.26). Data analysis (Table 4.7) 
showed an exothermic reaction, with low affinity, consequently Kd in the mM range. 
Although the dissociation constant of ∆2ABDa R169E (1.8 ± 0.1 mM) and the WT 
(1.2 ± 0.03 mM) is 50% different, it suggests that this arginine residue R169 is 
probably not involved in binding of PiP2. On the contrary, the mutant ∆2ABDa R192E 
(2.8 ± 0.1 mM) presents more than twofold difference in dissociation constant 
compared to the WT, indicating that this arginine residue R192, which is mapped to 
the end of α-helix C of CH2 domain (Figure 5.2), might play a role within the PiP2 
interaction site: R163, R169 and R192 according to studies on ABD crystal structure 
[numbers according α-actinin isoform 2; (Franzot et al., 2005)]. 
 Nevertheless, more accurate data need to be measured with the optimal 
protein concentration, a more suitable IP3 concentration and the ideal salt 
concentration (especially relevant in low affinity binding). Protein concentrations used 
in ITC experiments to verify reaction behaviour were based on the maximum 
concentration achievable for 2 ml of sample (technique limitation). With access to the 
new ITC machine (ITC200, MicroCal) in our laboratory, it will become possible to 
increase protein concentration easily, with a required sample volume ten times 
smaller (200 µl). 
 In addition to these binding studies, crystal soaking of ABD into IP3 or IP6 and 
co-crystallization of ABD with IP3 were set up in order to validate the proposed PiP2 
binding site within the ABD (Franzot et al., 2005). 6x His - 2ABDa WT was submitted 
to crystallization trials but since no crystal hits were obtained, the sample was 
subsequently submitted to TEV cleavage. The reaction was unsuccessful, possibly 
due to the fact that the TEV recognition site was not accessible to protease after the 
folding process. 
 A new ABD construct was, therefore, designed (2ABDY; Figure 5.3) based on 
the construct used to determine the crystal structure of α-actinin ABD isoform 3, 
which included the sixteen residues that precede the actin-binding domain of the 
ABDa construct (numbering according to α-actinin isoform 2). This construct initiates 
at the residue Y19, corresponding to the start of the first α-helix according to the 
secondary structure prediction (Figure 5.4). 
____________________________________________DISCUSSION AND PERSPECTIVES 
76 
 
 The 6x Histag was cleaved successfully and crystal hits on 2ABDY were 
readily obtained in several different conditions (Figures 4.27 and 4.28). 
 
 
 
Figure 5.3 Alignment of the four human α-actinin isoforms, showing the difference between 
constructs. The ABDa starts at the beginning of the actin-binding domain (ABD), while the ABDY 
construct is longer and based on the structure of human ABD isoform 3. The 2FLY construct starts at 
the same tyrosine residue (Y19) as for ABDY (Figure 3.1). The alignment was performed using the 
Multiple Sequence Alignment software (Corpet, 1988). 
 
 
 
 
Figure 5.4 N-terminal secondary structure prediction of 2ABD calculated by the software PSIPRED 
(Jones, 1999). C represents coil and H represents α-helix, which are also represented in green. In 
blue in represented the prediction confidence. 
 
 Soaking and co-crystallization experiments were set up using different IP3 or 
IP6 concentrations, in an attempt to obtain the protein-ligand complex under the 
crystallization process. Eight structures of 2ABDY were solved and analysed for the 
presence of the ligand, which was not found bound to ABD (section 4.9.6). The 
absence of bound ligand in the crystal structure might be due pH and precipitant 
agents concentrations used for crystallization that decrease the efficiency of binding, 
coupled to low intrinsic affinity as indicated by NMR and ITC experiments. 
 The 2ABDY crystal structure (Figure 4.30) was determined by molecular 
replacement using as a search model the structure of α-actinin ABD isoform 3 [PDB 
entry 1WKU; (Franzot et al., 2005)], which shares around 95% of identity with ABD 
isoform 2. As indicated from solvent content of 45% (Matthews B. W., 1968), two 
molecules in the asymmetric unit were searched for molecular replacement. 
Refinement and model statistics were very good already after a few cycles of 
refinement (Table 4.9). 
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 2ABDY presented closed conformation of the two CH domains as observed for 
the ABD structure of other actin-binding proteins such as S. pombe fimbrin, utrophin, 
dystrophin, human and mouse plectin, as well as the other isoforms of α-actinin. 
However in utrophin and dystrophin structures, the closed conformation is attained 
via a domain swapping between two molecules, a crystal artefact observed and 
recognized in macromolecular crystallography. ABD open conformation was 
observed in Arabidopsis thaliana fimbrin (Borrego-Diaz et al., 2006; Franzot et al., 
2005; Garcia-Alvarez et al., 2003; Goldsmith et al., 1997; Keep et al., 1999; Klein et 
al., 2004; Lee et al., 2008; Liu and Eisenberg, 2002; Sevcik et al., 2004). Comparison 
of 2ABDY refined structure with α-actinin isoforms 1, 3 and 4 (Figure 5.5) showed no 
significant differences in the overall structure, as indicated by r.m.s.d. after 
superposition of equivalent Cα atoms ranging from 0.34 to 0.46 Å. Although the 
interaction between CH1 and CH2 domains of ABD is maintained by the residues K 
and W in α-actinin isoforms 1, 3 and 4; this interaction is maintained by residues 
R243 and W136 in isoform 2 (Figure 5.5), where the aliphatic part of R246 side chain 
is involved in hydrophobic interaction with W136 side chain. 
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Figure 5.5 Structure superposition of human α-actinin ABD isoforms: 1 [pink; (Borrego-Diaz et al., 
2006)], 2 (blue, Figure 4.30); 3 [green; (Franzot et al., 2005)] and 4 [red; (Lee et al., 2008)]. Residues 
involved in the CH1 and CH2 domains interactions are highlighted in lines: residues W are conserved 
in all four isoforms; residues K are found in isoforms 1, 3 and 4, while R is found in isoform 2 (numbers 
according to isoform 2). 
 
5.3 Full length α-actinin 
5.3.1 Entamoeba histolytica α-actinin (2Eh) 
 E. histolytica α-actinin isoform 2 is smaller than its human equivalent, 
presenting only two spectrin-like repeats instead of four as found in α-actinins from 
higher phyla. The structural studies on E. histolytica isoform 2 were undertaken, as it 
was therefore believed to be less flexible and more prone to crystallize. 
 Several commercial screens, different crystallization temperatures and protein 
conditions (tagged, non-tagged and at different concentrations) were used for 
crystallization trials that did not result in crystal hits. DSF and protein reductive 
methylation were consequently carried out in the attempt to enhance protein stability 
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in solution (DSF, Table 4.3) and the crystal packing by changing surface properties 
(Walter et al., 2006). These strategies resulted in crystal hits in several different 
conditions (Figure 4.15) and the optimization is in progress. 
 
5.3.2 Human α-actinin isoform (2AFL) 
 Human α-actinin isoform 2 (2AFL) was submitted to crystallization trials using 
several commercial screens, different crystallization temperatures and protein 
conditions (tagged, non-tagged and in different concentrations). No crystal hits were 
obtained. 
 In order to increase protein stability in solution, DSF was employed to 
determine optimal buffer conditions. Crystallizations trails were repeated with the 
identified optimal buffer (Table 4.3), but they proved unsuccessful. 
 Protein reductive methylation resulted in initial crystalline hits, which could be 
optimized to clusters of tiny needles (6x His - 2AFL Met-K, Figure 4.16), which in turn 
could not be refined to larger single crystals. 
 Rational surface engineering was therefore used, applying the methodology of 
surface entropy reduction (SER) mutation, which can enhance formation of crystal 
contacts (Derewenda, 2004b). Two mutants were successfully produced: the triple-
site mutant 6x His – ∆2AFL E23A/E24A/E25A and the double-site mutant 6x His – 
∆2AFL E310A/K311A. According to protein expression and purification yields 
(section 4.7), the double-site mutant (6x His-tag ∆2AFL) was selected for further 
crystallization trials. The low protein yield observed for the triple mutant might be 
related to the importance of the N-terminal in protein folding or stability, since 
constructs with intact N-terminal (full length α-actinin, double-site mutant) do not 
show protein yield or stability problems. 
 Initial crystallization screens of the double-site mutant 6x His-tag ∆2AFL 
yielded crystalline hits (Figure 4.17), which were difficult to optimize. Protein 
reductive methylation (6x His-tag ∆2AFL Met-K) resulted in optimized single needles 
(Figure 4.18) that showed diffraction to resolution of 11 Å at ESRF beamline ID23-1. 
 In order to improve crystal quality and increase resolution limits, N-terminally 
truncated construct was designed (2AFLY), based on the same idea of keeping the 
integrity of the first α-helix used to design the construct 2ABDY (section 5.2; Figures 
5.3 and 5.4). In this case, the first eighteen residues were excluded from the 
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construct, which also started at residue 19Y (numbering according to α-actinin 
isoform 2). 
 Full length α-actinin WT and both SER mutants (6x His – ∆2AFL 
E23A/E24A/E25A and 6x His – ∆2AFL E310A/K311A) were submitted to DNA 
amplification and cloning with primers designed for the N-terminally truncated 
construct, following the same methodology (section 3.2). Successfully cloning, 
protein expression and purification were obtained only for the SER double-site 
mutant (∆2AFLY): 6x His – ∆2AFLY E310A/K311A. Crystallization trials for the new 
construct, ∆2AFLY, resulted in single needles after reductive methylation. The 
needles obtained for 6x His - ∆2AFLY Met-K (Figure 4.19) were notably bigger than 
those obtained for 6x His - ∆2AFL Met-K and a partial data set to resolution around 4 
Å was collected at the micro focus beamline ID23-2 (ESRF). 
 Three partial data sets were collected and merged during scaling, in an 
attempt to obtain a complete data set. Data were indexed and integrated in 
orthorhombic space group P222 but data quality and limited resolution prevented 
from discerning the real space groups P2221, P21212 and P212121 through analysis of 
systematic absences. The merged data were not of sufficient quality to solve the 
structure (Table 4.6). 
 Subsequently, the tag from 6x His - ∆2AFLY was cleaved and single crystals 
were obtained in different crystal forms after protein reductive methylation (∆2AFLY 
Met-K; Figure 4.20). X-ray data were collected at beamline ID23-1 (ESRF). Extensive 
screens of diffraction capacity of crystals (on average of ~ 80 crystals diffracted X-
ray) yielded diffraction data from one ∆2AFLY crystal to a resolution of around 4 Å. 
Higher resolution data were, however, of poor quality and a resolution cut-off at 6.7 Å 
was necessary to produce a complete data set with acceptable data statistics (Table 
4.7). The data were integrated on space group orthorhombic (P222) and as in the 
case of the tagged construct 6x His - ∆2AFLY Met-K, the real space group was not 
assigned due to the absence of high resolution data. 
 According to Matthews coefficient calculations [VM = 3.30 Å3.Da-1; (Matthews 
B. W., 1968)], the asymmetric unit of ∆2AFLY crystal could accommodate either one 
half dimer molecule (hd) or one full monomer. Considering α-actinin molecular 
architecture where two subunits are related by a twofold axis perpendicular to the 
central rod domain axis and the fact that the expected length of the full monomer (~ 
400 Å) is too long to fit in the asymmetric unit (a = 72.4 Å, b = 101.4 Å, c = 179.8 Å 
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and α = β = γ = 90°; Table 4.7), the unit cell packing accommodating the half dimer 
molecule is believed to be the most probable. 
 Improvement of crystal diffraction quality due to surface engineering plus 
design of an N-terminal truncated version of 2AFL is shown Figure 4.21. Protein 
surface charges might be affecting crystal packing, therefore, changes in surface 
properties induced by protein reductive methylation combined with SER mutation 
strategies enhanced crystallization propensity of ∆2AFLY, resulting in crystal hits. 
Further experimental optimizations are necessary to obtain diffraction data to higher 
resolution and quality. Two approaches combined with massive screening of crystals 
could be employed: protein reductive cyclic pentylation of free amines by 
glutaraldehyde (Vetting et al., 2009) and post-crystallization treatments, including 
crystal dehydratation [reviewed by (Heras and Martin, 2005)]. 
 
5.4 Protein-protein complex: α-actinin half dimer (hd) and PDZ domain of ZASP 
 It is known that the PDZ domain of ZASP interacts with the C-terminal region 
(EF-3/4) of α-actinin isoform 2 (Faulkner et al., 1999). This complex was used as a 
model to validate the regulation of α-actinin upon phosphatidylinositol (4, 5)-
biphosphate (PiP2) binding, in the context of antiparallel dimer where functional 
domains (ABD and CaM) are juxtaposed. Protein components of the complex 
formation were the half dimer of α-actinin isoform 2 (2hd) and the PDZ domain of 
ZASP. Lysophosphatidic acid (LPA) was used to check if it could enhance the 
complex formation, since it is more soluble than PiP2 and contains the same 
hydrophobic tail as PiP2 molecule. Therefore, LPA hydrophobic tail could disturb the 
interaction of N-terminal and C-terminal of α-actinin antiparallel subunits. 
 Complex formation studies were carried out by preparative and analytical size 
exclusion chromatography. The preparative size exclusion chromatography was used 
as a pilot experiment and resulted, in the absence of LPA, in a complex formation 
between the tagged PDZ and the excess of tagged α-actinin C-terminal part of the 
dimer (6x His – R3_SR4_CaM, Figure 4.13). Consequently, analytical size exclusion 
chromatography studies were performed to verify whether the LPA would enhance 
complex formation without any excess of 6x His – SR3_SR4_CaM. 
Different 2hd, PDZ and LPA molar ratios were prepared for the analytical 
studies. As can be seen in Figure 4.14 (D and E), a formation of a new peak is 
observed in the size exclusion chromatography elution profile in the presence of LPA. 
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This peak contains the 2hd molecule alone (Figure 4.14F), indicating that either the 
2hd is aggregating in the presence of LPA due to alterations in pH or 2hd is 
interacting with LPA. If the latter case occurred, it shows that although 2hd and LPA 
interact, no complex between α-actinin and PDZ domain of ZASP is formed under 
conditions used. 
 Since the binding affinity between the PDZ domain of ZASP and α-actinin EF-
3/4 is relatively weak [Kd = 35.6 µM; (Au et al., 2004)] the experimental condition 
used for SEC could have hindered binding or disturbed the complex formation. 
Another explanation could be that the head of LPA is not interacting properly with 
ABD, since it is considerably different from PiP2 soluble head, resulting in the tail not 
being positioned correctly to interfere with the binding of CaM domain of one subunit 
to the neck of the other subunit. 
 
5.5 Other constructs 
5.5.1 α-actinin domains complex 
 In order to understand the molecular architecture of α-actinin and the structural 
mechanisms underlying its regulation, the production of different complexes involving 
shorter N-terminal and C-terminal regions of α-actinin composed of only one or two 
consecutives domains (ABDa_SR1 and SR4_CaM, CaM or EF-3/4; Figure 3.1) was 
attempted for structural studies. Two different approaches were employed: co-
expression (Figure 4.3 and Table 4.2) and co-purification experiments (Figure 4.12), 
which both resulted in similar results: low purity, low concentration and insolubility 
issues (Figures 4.3 and 4.12), which made crystallization trials impossible. 
 
5.5.1.1 Co-expression 
 For co-expression experiments, complexes formation was attempted between 
tagged and/or non-tagged domains of α-actinin isoforms 1 and 2 (Figure 4.3 and 
Table 4.2). Different approaches to achieve high-level expression of the recombinant 
proteins were used, such as transforming several E. coli hosts with plasmids, cloning 
the fragments into different plasmids and over-expressing the recombinant protein at 
different temperatures [reviewed by (Makrides, 1996)]. 
 N-terminal and C-terminal constructs used were: the N-terminal part 
ABDa_SR1 (actinin binding domain plus spectrin-like repeat 1) and C-terminal part 
SR4_CaM (spectrin-like repeat 4 plus calmodulin like domain), CaM (calmodulin like 
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domain with 4 EF hands) or EF-3/4 (the last part of the calmodulin like domain with 
EF hands 3 and 4). Generally, a soluble C-terminal component and an insoluble N-
terminal component (Figure 4.3) were obtained. Since protein solubility was checked 
after a small scale over-expression assay and the protein yield was not high, the 
most promising soluble complex ABDa_SR1 (6x His-tag + TrxA tagged) and 
SR4_CaM (non-tagged) of α-actinin isoform 2 (Sample 15 in Figure 4.3) was 
selected for scale-up. Large scale over-expression experiment (Figure 4.11A, B) 
resulted in a complex of 2ABDa_SR1 + 2SR4_CaM complex (Figure 4.11C), which 
was neither sufficiently pure nor concentrated to allow for crystallization trials. 
 Over-expression of another protein of a molecular weight around 40 kDa was 
present in almost all tested conditions. It was speculated that it could be a product of 
ABDa_SR1 degradation, but since this protein is present even in the presence of 
protease inhibitors during cell lysis as well as when the protein expression is induced 
at 20°C. We believe that it could be one of the classical E. coli contaminants - 
chaperone protein DnaJ, which can be co-purified by IMAC, binding either to the 
recombinant protein or directly to the resin (Graslund et al., 2008). 
 
5.5.1.2 Co-purification 
 Co-purification experiments were carried out in attempt to obtain complexes of 
tagged and/or non-tagged domains of α-actinin isoforms 1 and 2. The components 
used in this study were ABDa_SR1 (6x His-tag + TrxA tagged) with CaM or EF-3/4, 
either tagged or non-tagged (Figure 3.1, Table 4.1). Results of gravity flow IMAC 
(Figure 4.12) show a low protein yield and purity and confirm the presence of the 
additional protein with a molecular weight around 40 kDa as obtained in the co-
expression experiments. 
 Another approach used to form a complex of α-actinin N-terminal and C-
terminal domains was based on purification of individual domains and subsequent 
complex formation after purification steps. TEV cleavage of the tag from 6x His - 
ABDa_SR1 resulted in protein aggregation, caused due to the hydrophobic patches 
found at the spectrin-like repeat 1 [SR1;(Ylanne et al., 2001a)] or not optimal 
cleavage conditions. Additionally, this aggregation could as well be a result of the 
absence of the N-terminal, which might be involved in protein folding or stability. As 
already mentioned, according to the secondary structure prediction (Figure 5.4), a 
construct starting at residue 35 (number corresponds to α-actinin isoform 2) is lacking 
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part of the first α-helix, which is probably disturbing the structural integrity of the 
protein. 
 
5.5.2 α-Actinin half dimer (hd) 
 The approach of generating α-actinin half of the dimer unit via bicistronic 
vector where the N-terminal is not tagged (ABD_SR1_SR2) and the C-terminal is 
tagged (6x His - SR3_SR4_CaM) proved to be the best way to purify a smaller 
version than α-actinin full length (AFL) homodimer (Figure 4.9). The stability of hd is 
comparable to the AFL dimer along the lines that the SR stabilize the dimer 
formation. 
 
5.5.3 Crystallization of other α-actinin constructs 
 Crystallization trails for α-actinin half dimer of both isoforms and the full length 
of isoform 1 were unsuccessful, even after protein reductive methylation. Strategies 
to obtain diffraction quality crystal will probably require involvement of surface 
engineering similar to what was applied to 2AFL, since protein reductive methylation 
alone did not yield crystal hits. 
 
5.6 Small angle X-ray scattering (SAXS): 2Eh, AFL and hd 
 SAXS derived molecular envelopes for human α-actinin full length and half 
dimers as well as on E. histolytica α-actinin (Figures 4.32 and 4.33) presented the 
expected sizes as estimated from structural information on individual domains: ABD 
(Franzot et al., 2005), central rod domain (Ylanne et al., 2001a) and EF-3/4 (Atkinson 
et al., 2001) and rigid body fitting, both presenting very good χ-values (around 1; 
Tables 4.10 and 4.11). 
 The molecular envelopes in all cases showed CaM in the proximity of ABD in 
close conformation (as observed in the ABD crystal structure, Figure 4.30). This 
structural information on α-actinin in solution sheds additional light on the question of 
open/closed conformation of ABD in α-actinin cryo EM study of frozen hydrated 2-D 
arrays of α-actinin rabbit muscle isoform showing ABD in open conformation (Tang et 
al., 2001) and 3-D reconstruction of chicken gizzard α-actinin in lipid layers revealed 
ABD in both open and closed conformation (Liu et al., 2004). 
 At the available SAXS data resolution (~20 Å), it was not possible to observe 
conformational changes in α-actinin N-terminal or C-terminal ends, when Ca2+ was 
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added to the sample, given that the expected changes are localized in the C-terminal 
calcium binding domain (CaM), which represents only ~ 7% of the scattering mass of 
entire dimer. Another reason for no observed conformational changes could be in the 
protein preparation, in what concerns the presence and absence of Ca2+ ions: if they 
were present from the starting point, changes upon addition of Ca2+ could not be 
triggered. New samples of full length α-actinin isoform 1 (Ca2+ sensitive) were, 
subsequently, prepared in a buffer containing Ca2+ (20 mM Tris-HCl pH 7.6, 150 mM 
NaCl, 2 mM CaCl2) or in a buffer excluding Ca2+ (20 mM Tris-HCl pH 7.6, 150 mM 
NaCl, 5 mM EDTA). Ca2+ ion chelating agent (EDTA) was added to insure that the α-
actinin sample was Ca2+ ion free. SAXS data from the two samples were collected 
and analysis is ongoing in collaboration with the SAXS group of EMBL-Hamburg 
(DESY). 
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6. CONCLUSIONS 
 
6.1 Actin binding domain (2ABD) 
Validation of the putative PiP2 binding site involved binding studies IP3 or IP6 
(phosphoinositides head group with three and six phosphates respectively) with ABD 
WT, PiP2 single-site mutants (two out of three residues predicted to be involved in 
PiP2 interaction mutated: ∆R169E and ∆R192E). 
Among all experiments performed to characterise the interaction (DSF, CD, 
NMR and ITC), ITC was the only that clearly showed binding, albeit weak. These 
results indicate that ABD and IP3 are low affinity binders in general and that residue 
192 (R192) might be an important player in this interaction, as the mutant ∆R192E 
showed a significantly lower affinity constant to IP3. 
 Besides these binding studies, crystallization trials were carried out in the 
presence of IP3 or IP6 by crystal soaking or co-crystallization. Crystal hits were 
obtained in several conditions and eight crystal structures could be determined to a 
resolution of 1.8 Å and analysed for ligand binding. No IP3 or IP6 were found bound 
to ABD and the absence of ligand in the structure could be attributed to the low 
affinity as seen in the binding studies, combined with crystallization conditions, which 
might not be optimal for binding. 
 
6.2 Full length α-actinin 
Due to its size and flexibility, full length α-actinin has been considered a 
recalcitrant protein to crystallization for a long time. Automation of crystallization 
procedures through implementation of robotics, able to set thousands of different 
conditions in a short time, and improvement of protein surface engineering 
methodologies have provided the necessary tools for α-actinin crystallization. 
Successful enhancement of crystal contacts and induced crystal growth were 
achieved through protein surface engineering methodologies (protein reductive 
methylation and surface entropy reduction - SER), giving these techniques an 
outstanding relevance for the results described in this thesis. 
Although E. histolytica α-actinin is a smaller version and distantly related to the 
human isoforms, crystal hits were obtained only after protein reductive methylation. 
For human α-actinin isoform 2, besides reductive methylation, SER mutations had to 
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be performed in order to obtain crystal hits, demonstrating critical interference of 
surface charges on the crystal packing process. 
Improvement of crystal diffraction quality for human α-actinin SER mutant 
(∆2AFL) correlated with employed strategies, becoming better with the truncated 
version SER mutant (∆2AFLY), after reductive methylation and His-tag cleavage. 
Nevertheless, these crystals diffracted to low resolution, making structure 
determination not amenable. 
 
6.3 Protein-protein complex: α-actinin half dimer (hd) and PDZ domain of ZASP 
Binding studies were performed to verify whether the hydrophobic tail of PiP2 
is able to enhance complex formation of ZASP and α-actinin. These studies were 
carried out using LPA since it contains the same hydrophobic tail as PiP2. No binding 
between α-actinin hd and PDZ domain of ZASP was observed under the 
experimental conditions used. The polar head of LPA might no interact strongly 
enough with ABD to bring about the hydrophobic tail, which hinders binding of α-
actinin N-terminal and C-terminal ends. Additionally, due to the low affinity constant 
of PDZ domain of ZASP and α-actinin EF-3/4, size exclusion chromatography might 
not be the best way to study this interaction. 
 
6.4 Final remark 
 Several questions concerning α-actinin regulation and its overall molecular 
architecture remain open, but the work described here contributed to bringing us 
closer than ever to answering them. 
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